{"SLR NAME":"Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis","References":[{"title1":"Impact of chronic liver disease on outcomes of hospitalized patients with COVID?19: A multicentre United States experience","References":[{"title2":"Latest updates","References":[]},{"title2":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","References":[{"title3":"The novel coronavirus originating in Wuhan, China: challenges for global health governance"},{"title3":"Severe acute respiratory syndrome-related coronavirus: the species and its viruses:a statement of the Coronavirus Study Group"},{"title3":"Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society"},{"title3":"KDIGO clinical practice guidelines for acute kidney injury"},{"title3":"Acute respiratory distress syndrome: the Berlin Definition"},{"title3":"Chinese management guideline for COVID-19 (version 6.0)"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Middle East respiratory syndrome"},{"title3":"Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong"},{"title3":"Predictors of mortality in Middle East respiratory syndrome (MERS)"},{"title3":"Exacerbated innate host response to SARS-CoV in aged non-human primates"},{"title3":"The immunopathogenesis of sepsis in elderly patients"},{"title3":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)"},{"title3":"Serial evaluation of the SOFA score to predict outcome in critically ill patients"},{"title3":"Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network"},{"title3":"Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study"},{"title3":"Acute pneumonia and the cardiovascular system"},{"title3":"Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis"},{"title3":"Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004-2015"},{"title3":"Prevalence and significance of coagulation abnormalities in community-acquired pneumonia"},{"title3":"D-dimer is a significant prognostic factor in patients with suspected infection and sepsis"},{"title3":"Risk of myocardial infarction and stroke after acute infection or vaccination"},{"title3":"Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality"},{"title3":"Cardiovascular complications of acute respiratory infections: current research and future directions"},{"title3":"Regulation of ACE2 in cardiac myocytes and fibroblasts"},{"title3":"ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase"},{"title3":"Viral shedding and antibody response in 37 patients with Middle East Respiratory Syndrome coronavirus infection"},{"title3":"Viral load kinetics of MERS coronavirus infection"},{"title3":"Factors associated with prolonged viral shedding in patients with avian influenza A(H7N9) virus infection"},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients"}]},{"title2":"Association of obesity with disease severity among patients with COVID-19","References":[{"title3":"Coronavirus investigating, and research team a novel coronavirus from patients with pneumonia in China 2019"},{"title3":"Organization WH. Coronavirus disease (COVID-19) pandemic-emergency use listing procedure (EUL) open for in vitro diagnostics. 2020-02-28) [2020-05-21]. https://www.who.int/diagnostics_laboratory/EUL/en. 2020"},{"title3":"Hypertension and its management in COVID-19 patients The assorted view"},{"title3":"COVID-19 and obesity: overlapping of two pandemics"},{"title3":"The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran"},{"title3":"Angiotensin-converting enzyme 2 (ACE2) in the pathogenesis of ARDS in COVID-19"},{"title3":"Characterization of apelin, the ligand for the APJ receptor"},{"title3":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase"},{"title3":"Apelin/APJ system a novel promising therapy target for thrombotic diseases"},{"title3":"Apelin/APJ system: an emerging therapeutic target for respiratory diseases"},{"title3":"Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system"},{"title3":"Circulating Apelin is increased in patients with type 1 or type 2 diabetes and is associated with better glycaemic control"},{"title3":"Relationships between plasma apelin and adiponectin with normal weight obesity, body composition, and cardiorespiratory fitness in working adults"},{"title3":"The investigation effect of weight loss on serum vaspin, apelin-13, and obestatin levels in obese individual"},{"title3":"The role of apelin in cardiovascular diseases"},{"title3":"Lowered circulating apelin is significantly associated with an increased risk for hypertension a meta-analysis"},{"title3":"COVID-19 and diabetes: a comprehensive review of angiotensin converting enzyme 2 mutual effects and pharmacotherapy"},{"title3":"Apelin an antithrombotic factor that inhibits platelet function"},{"title3":"Apelin and ACE2 in cardiovascular disease"},{"title3":"Coronary artery disease risk factors in an urban and peri-urban setting, Kerman, Southeastern Iran (KERCADR study): methodology and preliminary report"},{"title3":"Organization WH. Global database on Body Mass Index: BMI Classification. 2006. World Heal Organ Geneva, Switz. 2015"},{"title3":"COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors"},{"title3":"Apelin and visfatin plasma levels in healthy individuals with high normal blood pressure"},{"title3":"Comparison of two different applications of the griess method for nitric oxide measurement"},{"title3":"Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19"},{"title3":"Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats"},{"title3":"Apelin-13 administration protects against LPS-induced acute lung injury by inhibiting NF-kappaB pathway and NLRP3 inflammasome activation"},{"title3":"ACE2 elevation in severe COVID-19"},{"title3":"ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage"},{"title3":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2"},{"title3":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)"},{"title3":"Systemic hypoxia increases circulating concentration of apelin in humans"},{"title3":"An overview on biological functions and emerging therapeutic roles of apelin in diabetes mellitus"},{"title3":"Obesity as a risk factor for severe covid-19 and complications a review"}]},{"title2":"Effect of gastrointestinal symptoms on patients infected with coronavirus disease 2019","References":[]},{"title2":"Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms","References":[{"title3":"Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle"},{"title3":"Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak"},{"title3":"Potential for global spread of a novel coronavirus from China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus"},{"title3":"The association between domestic train transportation and novel coronavirus (2019-nCoV) outbreak in China from 2019 to 2020: a data-driven correlational report"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"The digestive system is a potentila route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes"},{"title3":"Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Coronavirus infections and immune responses"},{"title3":"Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: a single-center, descriptive study"},{"title3":"Dynamic RNA modifications in gene expression regulation"},{"title3":"N6-methyladenosine-dependent regulation of messenger RNA stability"},{"title3":"Posttranscriptional m(6)A Editing of HIV-1 mRNAs Enhances Viral Gene Expression"},{"title3":"N6-Methyladenosine in Flaviviridae viral RNA genomes regulates infection"},{"title3":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA"},{"title3":"Epitranscriptomic enhancement of influenza A virus gene expression and replication"},{"title3":"Epigenetic landscape during coronavirus infection"},{"title3":"Molecular mechanisms of coronavirus RNA capping and methylation"},{"title3":"A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence"},{"title3":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology"},{"title3":"Viral load of SARS-CoV-2 in clinical samples"}]},{"title2":"Burden of liver diseases in the world","References":[{"title3":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe"},{"title3":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis"},{"title3":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030"},{"title3":"Practice patterns in NAFLD and NASH: real life differs from published guidelines"},{"title3":"Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines"},{"title3":"Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging"},{"title3":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis"},{"title3":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology"},{"title3":"Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches"},{"title3":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with NASH and advanced fibrosis"},{"title3":"Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review"},{"title3":"Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease"},{"title3":"Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey Data"},{"title3":"NAFLD-the next global epidemic"},{"title3":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease"},{"title3":"Variables associated with inpatient and outpatient resource utilization among Medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis"},{"title3":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis"},{"title3":"Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation"},{"title3":"Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis"},{"title3":"Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study"},{"title3":"Cost-utility analysis of nonalcoholic steatohepatitis screening"},{"title3":"Burden of illness and economic model for patients with non-alcoholic steatohepatitis (NASH) in the United States"},{"title3":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?"},{"title3":"Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey"},{"title3":"The association between nonalcoholic fatty liver disease and cardiovascular disease outcomes"},{"title3":"Global epidemiology of nonalcoholic fatty liver disease:meta-analytic assessment of prevalence, incidence, and outcomes"},{"title3":"Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis Medicare patients"},{"title3":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy"},{"title3":"Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data"},{"title3":"Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis"},{"title3":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases"},{"title3":"Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study"},{"title3":"Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?"},{"title3":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994"},{"title3":"Healthcare resource utilization, demographics, and comorbidities in non-alcoholic fatty liver disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) and progressive stages in a large, integrated healthcare delivery system [Abstract]"},{"title3":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management"},{"title3":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes"},{"title3":"Prevalence of the metabolic syndrome in the United States, 2003-2012"},{"title3":"Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes"},{"title3":"Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large US claims database"},{"title3":"All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the united states: a managed care perspective"},{"title3":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis"},{"title3":"The co-existence of nash and chronic kidney disease boosts cardiovascular risk: are there any common therapeutic options?"},{"title3":"Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities"},{"title3":"NASH therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs"},{"title3":"Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease"},{"title3":"Estimating the real-world cost of diabetes mellitus in the united states during an 8-year period using 2 cost methodologies"},{"title3":"All-cause costs increase exponentially with increased chronic kidney disease stage"},{"title3":"Medical care costs among patients with established cardiovascular disease"},{"title3":"Vitamin D: a new player in non-alcoholic fatty liver disease?"},{"title3":"Effect of vitamin D on non-alcoholic fatty liver disease: a systematic review of randomized controlled clinical trials"},{"title3":"Vitamin D supplementation and non-alcoholic fatty liver disease: present and future"},{"title3":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis"},{"title3":"Truven health analytics marketscan databases for clinical research in colon and rectal surgery"}]},{"title2":"Liver injury in COVID-19: management and challenges","References":[{"title3":"The cytokine storm and COVID-19"},{"title3":"Kidney diseases and COVID-19 infection: causes and effect, supportive therapeutics and nutritional perspectives"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"COVID-19 and liver disease"},{"title3":"COVID-19 and the liver"},{"title3":"Liver Dysfunction Is Associated with Long-Term Mortality in Septic Shock"},{"title3":"Review article: COVID-19 and liver disease-what we know on 1st May 2020"},{"title3":"Gastrointestinal and liver manifestations in patients with COVID-19"},{"title3":"Liver diseases in COVID-19: Etiology, treatment and prognosis"},{"title3":"COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies"},{"title3":"Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis"},{"title3":"Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis"},{"title3":"A Case Series of Children With 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features"},{"title3":"Clinical characteristics of 82 cases of death from COVID-19"},{"title3":"Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort"},{"title3":"Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding"},{"title3":"SARS-CoV-2 Infection in Children"},{"title3":"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study"},{"title3":"Clinical Features of COVID-19-Related Liver Functional Abnormality"},{"title3":"Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China"},{"title3":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area"},{"title3":"Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series"},{"title3":"Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China"},{"title3":"Liver tests abnormalities in COVID-19: trick or treat?"},{"title3":"Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic"},{"title3":"Health Status of Patients Who Underwent Liver Transplantation During the Coronavirus Outbreak at a Large Center in Milan, Italy"},{"title3":"COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission"},{"title3":"COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract"},{"title3":"Liver injury in COVID-19: management and challenges"},{"title3":"Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease"},{"title3":"Coronavirus infections and immune responses"},{"title3":"Apoptosis: a mechanism of acute and chronic liver injury"},{"title3":"SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases"},{"title3":"Proteomics. Tissue-based map of the human proteome"},{"title3":"COVID-19 in a designated infectious diseases hospital outside Hubei Province, China"},{"title3":"Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)"},{"title3":"A literature review for the mechanisms of stress-induced liver injury"},{"title3":"Mechanisms and treatment of organ failure in sepsis"},{"title3":"Liver - guardian, modifier and target of sepsis"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"},{"title3":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase"},{"title3":"The emerging role of ACE2 in physiology and disease"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor"},{"title3":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein"},{"title3":"Human neutralizing antibodies elicited by SARS-CoV-2 infection"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes"},{"title3":"The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects"},{"title3":"A phase I trial of intravenous interleukin-6 in patients with advanced cancer"},{"title3":"Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells"},{"title3":"Systemic inflammation as fuel for acute liver injury in COVID-19"},{"title3":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality"},{"title3":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?"},{"title3":"Liver injury during highly pathogenic human coronavirus infections"},{"title3":"SARS-CoV-2: a storm is raging"},{"title3":"In the eye of the COVID-19 cytokine storm"},{"title3":"Viral and host factors related to the clinical outcome of COVID-19"},{"title3":"Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)"},{"title3":"Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China"},{"title3":"Use of lactate dehydrogenase to evaluate the anti-viral activity against influenza A virus"},{"title3":"Lactate dehydrogenase leakage as a marker for apoptotic cell degradation induced by influenza virus infection in human fetal membrane cells"},{"title3":"Adipokines: molecular links between obesity and atheroslcerosis"},{"title3":"A new perspective on C-reactive protein in H7N9 infections"},{"title3":"C-reactive protein as a biomarker of severe H1N1 influenza"},{"title3":"Cognitive decline in Parkinson disease"},{"title3":"Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Digestive Manifestations in Patients Hospitalized With Coronavirus Disease 2019"},{"title3":"Effect of Gastrointestinal Symptoms in Patients With COVID-19"},{"title3":"Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study"},{"title3":"AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19"},{"title3":"Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study"},{"title3":"Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19)"},{"title3":"COVID-19 and liver injury: where do we stand?"},{"title3":"Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection"},{"title3":"Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China"},{"title3":"Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement"},{"title3":"COVID-19: Abnormal liver function tests"},{"title3":"Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19"},{"title3":"Hepatic manifestations of COVID-19"},{"title3":"Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies"},{"title3":"Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis"},{"title3":"Acute Liver Failure in a COVID-19 Patient Without any Preexisting Liver Disease"},{"title3":"Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study"},{"title3":"Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19"},{"title3":"Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study"},{"title3":"Gastrointestinal and Hepatic Manifestations of COVID-19: Evolving Recognition and Need for Increased Understanding in Vulnerable Populations"},{"title3":"Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study"},{"title3":"COVID-19 in solid organ transplant recipients: A single-center case series from Spain"},{"title3":"COVID-19 in solid organ transplant recipients: Initial report from the US epicenter"},{"title3":"COVID-19 in solid organ transplantation patients: A systematic review"},{"title3":"Tocilizumab and liver injury in patients with COVID-19"},{"title3":"A Novel Coronavirus from Patients with Pneumonia in China, 2019"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor"},{"title3":"A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?"},{"title3":"Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19"},{"title3":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19"},{"title3":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir"},{"title3":"Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study"},{"title3":"Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives"},{"title3":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies"},{"title3":"The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design"},{"title3":"Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms"},{"title3":"Remdesivir for the Treatment of Covid-19 - Final Report"},{"title3":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19"},{"title3":"Liver injury in remdesivir-treated COVID-19 patients"},{"title3":"Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019"},{"title3":"Etiology and management of liver injury in patients with COVID-19"},{"title3":"Therapeutic Potential for Tetracyclines in the Treatment of COVID-19"},{"title3":"Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study"},{"title3":"Azithromycin augments rhinovirus-induced IFNbeta via cytosolic MDA5 in experimental models of asthma exacerbation"},{"title3":"Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 Levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis"},{"title3":"Azithromycin for COVID-19: More Than Just an Antimicrobial?"},{"title3":"Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective"},{"title3":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection"},{"title3":"First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19"},{"title3":"Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics"},{"title3":"Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine"},{"title3":"Liver Injury in COVID-19: Caution and Management"},{"title3":"Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient"},{"title3":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)"},{"title3":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review"},{"title3":"Tocilizumab and COVID-19"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report"},{"title3":"Polygalasaponin F treats mice with pneumonia induced by influenza virus"},{"title3":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study"},{"title3":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro"},{"title3":"The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells"},{"title3":"Ritonavir and Lopinavir Suppress RCE1 and CAAX Rab Proteins Sensitizing the Liver to Organelle Stress and Injury"},{"title3":"Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature"},{"title3":"Protective effect of bicyclol on lipopolysaccharide-induced acute lung injury in mice"},{"title3":"Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms"},{"title3":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study"},{"title3":"Current pharmacological treatments for COVID-19: What's next?"},{"title3":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity"},{"title3":"COVID-19: A review of the proposed pharmacological treatments"},{"title3":"Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis"},{"title3":"Chloroquine attenuates paraquat-induced lung injury in mice by altering inflammation, oxidative stress and fibrosis"},{"title3":"Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055"},{"title3":"The gut microbiota and host health: a new clinical frontier"},{"title3":"Contributions of the intestinal microbiome in lung immunity"},{"title3":"Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19"},{"title3":"Assessment of Renal and Hepatic Tissue-Protective Effects of N-Acetylcysteine via Ammonia Metabolism: A Prospective Randomized Study"},{"title3":"Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?"},{"title3":"Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke"},{"title3":"Could Vitamins Help in the Fight Against COVID-19?"},{"title3":"Role of vitamin E in nonalcoholic fatty liver disease"},{"title3":"Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths"},{"title3":"Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies"},{"title3":"Potential protection of vitamin C against liver-lesioned mice"},{"title3":"Zinc and COVID-19: Basis of Current Clinical Trials"},{"title3":"Zinc and liver disease"},{"title3":"Possibility of magnesium supplementation for supportive treatment in patients with COVID-19"},{"title3":"Magnesium and liver disease"},{"title3":"COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2"},{"title3":"Is copper beneficial for COVID-19 patients?"},{"title3":"Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats"},{"title3":"Corticosteroids in Acute Lung Injury: The Dilemma Continues"}]},{"title2":"Clinical features of COVID-19-Related Liver Damage","References":[]},{"title2":"COVID-19: Abnormal liver function tests","References":[]},{"title2":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China","References":[]},{"title2":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study","References":[{"title3":"Novel coronavirus:China"},{"title3":"Coronavirus disease (COVID-19) outbreak"},{"title3":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission"},{"title3":"Notes from the field: a novel coronavirus genome identified in a cluster of pneumonia cases:Wuhan, China 2019-2020"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Novel coronavirus:Thailand (ex-China)"},{"title3":"Novel coronavirus:Japan (ex-China)"},{"title3":"Novel coronavirus:Republic of Korea (ex-China)"},{"title3":"First travel-related case of 2019 novel coronavirus detected in United States"},{"title3":"A cluster of cases of severe acute respiratory syndrome in Hong Kong"},{"title3":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study"},{"title3":"Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance"},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome"},{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Epidemiological, clinical and viral characteristics of fatal cases of human avian influenza A (H7N9) virus in Zhejiang Province, China"},{"title3":"Clinical features and factors associated with outcomes of patients infected with a novel influenza A (H7N9) virus: a preliminary study"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings"},{"title3":"Severe acute respiratory syndrome: radiographic and CT findings"},{"title3":"Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease"},{"title3":"Clinical and imaging findings in patients with severe acute respiratory syndrome"},{"title3":"CT correlation with outcomes in 15 patients with acute Middle East respiratory syndrome coronavirus"},{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings"},{"title3":"Acute Middle East respiratory syndrome coronavirus: temporal lung changes observed on the chest radiographs of 55 patients"},{"title3":"The radiologic manifestations of H5N1 avian influenza"},{"title3":"Organizing pneumonia: perilobular pattern at thin-section CT"},{"title3":"An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias"}]},{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia."},{"title3":"Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2."},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"First case of 2019 novel Coronavirus in the United States."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome."},{"title3":"A preventive and control strategy for COVID-19 infection: an experience from a Third-Tier Chinese City."},{"title3":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies."},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China."},{"title3":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2."},{"title3":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics."},{"title3":"Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia."},{"title3":"On the use of corticosteroids for 2019-nCoV pneumonia."},{"title3":"Comprehensive analysis of drugs to treat SARSCoV2 infection: mechanistic insights into current COVID19 therapies (Review)."},{"title3":"The role of telemedicine during the COVID-19 epidemic in China-experience from Shandong province."},{"title3":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial."},{"title3":"Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia."},{"title3":"Flattening the COVID-19 curve with natural killer cell based immunotherapies."},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."},{"title3":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event."},{"title3":"Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China."},{"title3":"Spatio-temporal metabolokinetics and efficacy of human placenta-derived mesenchymal stem/stromal cells on mice with refractory Crohn's-like enterocutaneous fistula."},{"title3":"High-efficient generation of VCAM-1(+) mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice."},{"title3":"Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease."},{"title3":"JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia."},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome."},{"title3":"Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review."},{"title3":"Three emerging coronaviruses in two decades."},{"title3":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future."},{"title3":"Coronaviruses - drug discovery and therapeutic options."},{"title3":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."},{"title3":"Acute respiratory distress syndrome: the Berlin Definition."},{"title3":"Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference."},{"title3":"Eicosanoid storm in infection and inflammation."},{"title3":"Decoding the enigma of antiviral crisis: does one target molecule regulate all?"}]},{"title2":"Coronavirus disease 2019 and prevalence of chronic liver disease: a meta-analysis","References":[]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]},{"title2":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area","References":[]},{"title2":"Obesity in the critically ill: a narrative review","References":[]},{"title2":"Body mass index is associated with the development of acute respiratory distress syndrome","References":[{"title3":"Obesity as a medical problem"},{"title3":"Excess deaths associated with underweight, overweight, and obesity"},{"title3":"Body mass index and outcomes in critically injured blunt trauma patients: weighing the impact"},{"title3":"Obesity in critical care"},{"title3":"Obesity-related excess mortality rate in an adult intensive care unit: A risk-adjusted matched cohort study"},{"title3":"Outcome of morbid obesity in the intensive care unit"},{"title3":"Body mass index is independently associated with hospital mortality in mechanically ventilated adults with acute lung injury"},{"title3":"The association between body mass index and clinical outcomes in acute lung injury"},{"title3":"Effect of obesity on intensive care morbidity and mortality: a meta-analysis"},{"title3":"Incidence and outcomes of acute lung injury"},{"title3":"Excess body weight is not independently associated with outcome in mechanically ventilated patients with acute lung injury"},{"title3":"Clinical predictors of and mortality in acute respiratory distress syndrome: Potential role of red cell transfusion"},{"title3":"Interobserver variation in interpreting chest radiographs for the diagnosis of acute respiratory distress syndrome"},{"title3":"Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome"},{"title3":"Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults"},{"title3":"Peri-operative risk factors for acute lung injury after elective oesophagectomy"},{"title3":"Risk factors for early primary graft dysfunction after lung transplantation: a registry study"},{"title3":"Ventilator-induced lung injury: from the bench to the bedside"},{"title3":"Risk factors for ARDS in patients receiving mechanical ventilation for &gt; 48 h"},{"title3":"Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients"},{"title3":"Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation"},{"title3":"Obesity and infection"},{"title3":"Intensive-Care Patients with Severe Novel Influenza A (H1N1) Virus Infection- Michigan, June 2009"},{"title3":"Impact of obesity in mechanically ventilated patients: a prospective study"},{"title3":"Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states"},{"title3":"Influence of obesity on sepsis"},{"title3":"Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome"},{"title3":"Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury"},{"title3":"Leptin regulates proinflammatory immune responses"},{"title3":"Leptin resistance protects mice from hyperoxia-induced acute lung injury"},{"title3":"ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin"},{"title3":"Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury"},{"title3":"The relationship between body mass index and postoperative mortality from critical illness"},{"title3":"Body mass index. An additional prognostic factor in ICU patients"}]},{"title2":"Obstructive sleep apnea, obesity, and the development of acute respiratory distress syndrome","References":[]},{"title2":"Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the framingham heart study","References":[{"title3":"Global epidemiology of nonalcoholic fatty liver disease:Meta-analytic assessment of prevalence, incidence, and outcomes"},{"title3":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases"},{"title3":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe"},{"title3":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease"},{"title3":"Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study"},{"title3":"Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: The coronary artery risk development in young adults study"},{"title3":"Nonalcoholic fatty liver disease and vascular function: Cross-sectional analysis in the Framingham Heart Study"},{"title3":"C-reactive protein, fibrinogen, and cardiovascular disease prediction"},{"title3":"Adipokines: A link between obesity and cardiovascular disease"},{"title3":"Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study"},{"title3":"One-year follow-up of clinical, metabolic and oxidative stress profile of morbid obese patients after laparoscopic sleeve gastrectomy. 8-oxo-dG as a clinical marker"},{"title3":"Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease"},{"title3":"Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: A case-control study in China"},{"title3":"Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults"},{"title3":"Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake"},{"title3":"Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease"},{"title3":"Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2"},{"title3":"Association of serum lipoprotein-associated phospholipase A2 level with nonalcoholic fatty liver disease"},{"title3":"Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease"},{"title3":"Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis"},{"title3":"Circulating soluble CD163 is associated with steatohepatitis and advanced fibrosis in nonalcoholic fatty liver disease"},{"title3":"Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease"},{"title3":"Beyond insulin resistance in NASH: TNF-alpha or adiponectin?"},{"title3":"Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease"},{"title3":"High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH"},{"title3":"Adipokines and cytokines in non-alcoholic fatty liver disease"},{"title3":"NASH predicts plasma inflammatory biomarkers independently of visceral fat in men"},{"title3":"Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E"},{"title3":"Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue"},{"title3":"Levels of soluble CD40 ligand and p-selectin in nonalcoholic fatty liver disease"},{"title3":"The association of inflammatory markers with nonalcoholic fatty liver disease differs by HIV serostatus"},{"title3":"Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane"},{"title3":"Association between inflammatory markers and liver fat: The Multi-Ethnic Study of Atherosclerosis"},{"title3":"Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease"},{"title3":"Liver fat is reproducibly measured using computed tomography in the Framingham Heart Study"},{"title3":"An approach to longitudinal studies in a community: the Framingham Study"},{"title3":"Alcoholic liver disease"},{"title3":"Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham heart study"},{"title3":"Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham study"},{"title3":"Comparison of anthropometric, area- and volume-based assessment of abdominal subcutaneous and visceral adipose tissue volumes using multi-detector computed tomography"},{"title3":"Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: The Framingham Heart Study"},{"title3":"Inflammatory biomarkers are associated with total brain volume"},{"title3":"Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing"},{"title3":"Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway"},{"title3":"Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes"},{"title3":"Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells"},{"title3":"Prevention of free fatty acid-induced lipid accumulation, oxidative stress, and cell death in primary hepatocyte cultures by a Gynostemma pentaphyllum extract"},{"title3":"NF-kB, Inflammation, and Metabolic Disease"},{"title3":"Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB"},{"title3":"Depletion of Liver Kupffer Cells Prevents the Development of Diet-Induced Hepatic Steatosis and Insulin Resistance"},{"title3":"Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis"},{"title3":"P-selectin and subclinical and clinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)"},{"title3":"Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study"},{"title3":"Stress cardiomyopathy: diagnosis, pathophysiology, management, and prognosis"},{"title3":"Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice"},{"title3":"The relationship between carotid atherosclerosis, inflammatory cytokines, and oxidative stress in middle-aged and elderly hemodialysis patients"},{"title3":"Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study"},{"title3":"Prevalence of non-Alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States"},{"title3":"Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis"},{"title3":"Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham heart study"},{"title3":"Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities"},{"title3":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study"},{"title3":"Markers of inflammation and their clinical significance"},{"title3":"Myeloperoxidase and cardiovascular disease"},{"title3":"Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects"},{"title3":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies"},{"title3":"Soluble tumor necrosis factor receptors and arterial stiffness in patients with coronary atherosclerosis"},{"title3":"Measurement of F2-Isoprostanes as an index of oxidative stress in vivo"}]},{"title2":"Association between non-alcoholic fatty liver disease and decreased lung function in adults: a systematic review and meta-analysis","References":[]},{"title2":"Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study","References":[]}]},{"title1":"Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19","References":[{"title2":"An interactive web-based dashboard to track COVID-19 in real time","References":[{"title3":"WHO statement regarding cluster of pneumonia cases in Wuhan, China"},{"title3":"Coronavirus disease 2019 (COVID-19) situation reports"},{"title3":"Tracking the epidemic"}]},{"title2":"Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study","References":[{"title3":"The novel coronavirus originating in Wuhan, China: Challenges for global health governance"},{"title3":"SARS-CoV-2 is an appropriate name for the new coronavirus"},{"title3":"Are high-performing health systems resilient against the COVID-19 epidemic?"},{"title3":"The SARS-CoV-2 outbreak: Diagnosis, infection prevention, and public perception"},{"title3":"The 2019 novel coronavirus outbreak:A global threat"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study"},{"title3":"2019 novel coronavirus infection and gastrointestinal tract"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region [in Chinese]"},{"title3":"Novel coronavirus pneumonia related liver injury: Etiological analysis and treatment strategy [in Chinese]"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study"},{"title3":"Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia [in Chinese]"},{"title3":"Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China"},{"title3":"Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests"},{"title3":"Evidence for gastrointestinal infection of SARS-CoV-2"},{"title3":"Symbiotic gut microbes modulate human metabolic phenotypes"},{"title3":"Emerging pathogenic links between microbiota and the gut-lung axis"},{"title3":"Gut-lung axis: The microbial contributions and clinical implications"},{"title3":"Clinical characteristics of imported cases of COVID-19 in Jiangsu province: A multicenter descriptive study"}]},{"title2":"Liver injury in COVID-19: management and challenges","References":[{"title3":"The cytokine storm and COVID-19"},{"title3":"Kidney diseases and COVID-19 infection: causes and effect, supportive therapeutics and nutritional perspectives"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"COVID-19 and liver disease"},{"title3":"COVID-19 and the liver"},{"title3":"Liver Dysfunction Is Associated with Long-Term Mortality in Septic Shock"},{"title3":"Review article: COVID-19 and liver disease-what we know on 1st May 2020"},{"title3":"Gastrointestinal and liver manifestations in patients with COVID-19"},{"title3":"Liver diseases in COVID-19: Etiology, treatment and prognosis"},{"title3":"COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies"},{"title3":"Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis"},{"title3":"Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis"},{"title3":"A Case Series of Children With 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features"},{"title3":"Clinical characteristics of 82 cases of death from COVID-19"},{"title3":"Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort"},{"title3":"Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding"},{"title3":"SARS-CoV-2 Infection in Children"},{"title3":"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study"},{"title3":"Clinical Features of COVID-19-Related Liver Functional Abnormality"},{"title3":"Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China"},{"title3":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area"},{"title3":"Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series"},{"title3":"Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China"},{"title3":"Liver tests abnormalities in COVID-19: trick or treat?"},{"title3":"Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic"},{"title3":"Health Status of Patients Who Underwent Liver Transplantation During the Coronavirus Outbreak at a Large Center in Milan, Italy"},{"title3":"COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission"},{"title3":"COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract"},{"title3":"Liver injury in COVID-19: management and challenges"},{"title3":"Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease"},{"title3":"Coronavirus infections and immune responses"},{"title3":"Apoptosis: a mechanism of acute and chronic liver injury"},{"title3":"SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases"},{"title3":"Proteomics. Tissue-based map of the human proteome"},{"title3":"COVID-19 in a designated infectious diseases hospital outside Hubei Province, China"},{"title3":"Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)"},{"title3":"A literature review for the mechanisms of stress-induced liver injury"},{"title3":"Mechanisms and treatment of organ failure in sepsis"},{"title3":"Liver - guardian, modifier and target of sepsis"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"},{"title3":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase"},{"title3":"The emerging role of ACE2 in physiology and disease"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor"},{"title3":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein"},{"title3":"Human neutralizing antibodies elicited by SARS-CoV-2 infection"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes"},{"title3":"The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects"},{"title3":"A phase I trial of intravenous interleukin-6 in patients with advanced cancer"},{"title3":"Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells"},{"title3":"Systemic inflammation as fuel for acute liver injury in COVID-19"},{"title3":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality"},{"title3":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?"},{"title3":"Liver injury during highly pathogenic human coronavirus infections"},{"title3":"SARS-CoV-2: a storm is raging"},{"title3":"In the eye of the COVID-19 cytokine storm"},{"title3":"Viral and host factors related to the clinical outcome of COVID-19"},{"title3":"Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)"},{"title3":"Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China"},{"title3":"Use of lactate dehydrogenase to evaluate the anti-viral activity against influenza A virus"},{"title3":"Lactate dehydrogenase leakage as a marker for apoptotic cell degradation induced by influenza virus infection in human fetal membrane cells"},{"title3":"Adipokines: molecular links between obesity and atheroslcerosis"},{"title3":"A new perspective on C-reactive protein in H7N9 infections"},{"title3":"C-reactive protein as a biomarker of severe H1N1 influenza"},{"title3":"Cognitive decline in Parkinson disease"},{"title3":"Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Digestive Manifestations in Patients Hospitalized With Coronavirus Disease 2019"},{"title3":"Effect of Gastrointestinal Symptoms in Patients With COVID-19"},{"title3":"Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study"},{"title3":"AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19"},{"title3":"Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study"},{"title3":"Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19)"},{"title3":"COVID-19 and liver injury: where do we stand?"},{"title3":"Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection"},{"title3":"Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China"},{"title3":"Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement"},{"title3":"COVID-19: Abnormal liver function tests"},{"title3":"Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19"},{"title3":"Hepatic manifestations of COVID-19"},{"title3":"Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies"},{"title3":"Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis"},{"title3":"Acute Liver Failure in a COVID-19 Patient Without any Preexisting Liver Disease"},{"title3":"Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study"},{"title3":"Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19"},{"title3":"Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study"},{"title3":"Gastrointestinal and Hepatic Manifestations of COVID-19: Evolving Recognition and Need for Increased Understanding in Vulnerable Populations"},{"title3":"Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study"},{"title3":"COVID-19 in solid organ transplant recipients: A single-center case series from Spain"},{"title3":"COVID-19 in solid organ transplant recipients: Initial report from the US epicenter"},{"title3":"COVID-19 in solid organ transplantation patients: A systematic review"},{"title3":"Tocilizumab and liver injury in patients with COVID-19"},{"title3":"A Novel Coronavirus from Patients with Pneumonia in China, 2019"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor"},{"title3":"A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?"},{"title3":"Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19"},{"title3":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19"},{"title3":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir"},{"title3":"Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study"},{"title3":"Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives"},{"title3":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies"},{"title3":"The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design"},{"title3":"Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms"},{"title3":"Remdesivir for the Treatment of Covid-19 - Final Report"},{"title3":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19"},{"title3":"Liver injury in remdesivir-treated COVID-19 patients"},{"title3":"Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019"},{"title3":"Etiology and management of liver injury in patients with COVID-19"},{"title3":"Therapeutic Potential for Tetracyclines in the Treatment of COVID-19"},{"title3":"Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study"},{"title3":"Azithromycin augments rhinovirus-induced IFNbeta via cytosolic MDA5 in experimental models of asthma exacerbation"},{"title3":"Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 Levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis"},{"title3":"Azithromycin for COVID-19: More Than Just an Antimicrobial?"},{"title3":"Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective"},{"title3":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection"},{"title3":"First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19"},{"title3":"Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics"},{"title3":"Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine"},{"title3":"Liver Injury in COVID-19: Caution and Management"},{"title3":"Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient"},{"title3":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)"},{"title3":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review"},{"title3":"Tocilizumab and COVID-19"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report"},{"title3":"Polygalasaponin F treats mice with pneumonia induced by influenza virus"},{"title3":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study"},{"title3":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro"},{"title3":"The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells"},{"title3":"Ritonavir and Lopinavir Suppress RCE1 and CAAX Rab Proteins Sensitizing the Liver to Organelle Stress and Injury"},{"title3":"Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature"},{"title3":"Protective effect of bicyclol on lipopolysaccharide-induced acute lung injury in mice"},{"title3":"Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms"},{"title3":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study"},{"title3":"Current pharmacological treatments for COVID-19: What's next?"},{"title3":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity"},{"title3":"COVID-19: A review of the proposed pharmacological treatments"},{"title3":"Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis"},{"title3":"Chloroquine attenuates paraquat-induced lung injury in mice by altering inflammation, oxidative stress and fibrosis"},{"title3":"Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055"},{"title3":"The gut microbiota and host health: a new clinical frontier"},{"title3":"Contributions of the intestinal microbiome in lung immunity"},{"title3":"Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19"},{"title3":"Assessment of Renal and Hepatic Tissue-Protective Effects of N-Acetylcysteine via Ammonia Metabolism: A Prospective Randomized Study"},{"title3":"Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?"},{"title3":"Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke"},{"title3":"Could Vitamins Help in the Fight Against COVID-19?"},{"title3":"Role of vitamin E in nonalcoholic fatty liver disease"},{"title3":"Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths"},{"title3":"Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies"},{"title3":"Potential protection of vitamin C against liver-lesioned mice"},{"title3":"Zinc and COVID-19: Basis of Current Clinical Trials"},{"title3":"Zinc and liver disease"},{"title3":"Possibility of magnesium supplementation for supportive treatment in patients with COVID-19"},{"title3":"Magnesium and liver disease"},{"title3":"COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2"},{"title3":"Is copper beneficial for COVID-19 patients?"},{"title3":"Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats"},{"title3":"Corticosteroids in Acute Lung Injury: The Dilemma Continues"}]},{"title2":"High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry","References":[{"title3":"Contemporary epidemiology of chronic liver disease and cirrhosis"},{"title3":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance"},{"title3":"Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper"},{"title3":"Cardiovascular disease, drug therapy, and mortality in Covid-19"},{"title3":"Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010"},{"title3":"Influenza virus infection as precipitating event of acute-on-chronic liver failure"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"}]},{"title2":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","References":[{"title3":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study"},{"title3":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association"},{"title3":"Non-alcoholic fatty liver disease: The diagnosis and management"},{"title3":"Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome"},{"title3":"Non alcoholic fatty liver disease and metabolic syndrome"},{"title3":"Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. Asia-Pacific Working Party on NAFLD"},{"title3":"Epidemiology of non-alcoholic fatty liver disease"},{"title3":"Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey"},{"title3":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis"},{"title3":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population"},{"title3":"Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis"},{"title3":"External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver Disease in a Population-based Study"},{"title3":"External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan"},{"title3":"Non-laboratory-based self-assessment screening score for non-alcoholic Fatty liver disease: development, validation and comparison with other scores"},{"title3":"External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals"},{"title3":"Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese"},{"title3":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD"},{"title3":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity"},{"title3":"Non-invasive diagnosis of non-alcoholic fatty liver disease: A critical appraisal"},{"title3":"Noninvasive evaluation of NAFLD"},{"title3":"A position statement on NAFLD/NASH based on the EASL 2009 special conference"},{"title3":"NCHS. National Health and Nutrition Examination Survey (NHANES). Available at: http://www.cdc.gov/nchs/nhanes.htm (accessed September 26, 2015)."},{"title3":"National Health and Nutrition Examination Survey: Plan and operations, 1999-2010. National Center for Health Statistics"},{"title3":"Data Linkage Team. &quot;Comparative analysis of the NHIS public-use and restricted-use linked mortality files: 2015 public-use data release&quot; National Center for Health Statistics. February 2015. Hyattsville, Maryland."},{"title3":"National Center for Health Statistics. Office of Analysis and Epidemiology, NCHS 2011 Linked Mortality Files Matching Methodology, September, 2013. Hyattsville, Maryland. Available at the following address: http://www.cdc.gov/nchs/data_access/data_linkage/mortality/linkage_methods_analytical_support/2011_linked_mor tality_file_matching_methodology.pdf"},{"title3":"Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease"},{"title3":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report"},{"title3":"Use and abuse of HOMA modeling"},{"title3":"National Health and Nutrition Examination Survey: Analytic guidelines, 1999-2010. National Center for Health Statistics"},{"title3":"NCHS. Key Concepts About Weighting in NHANES. Available at: http://www.cdc.gov/nchs/tutorials/NHANES/SurveyDesign/Weighting/OverviewKey.htm (accessed September 26, 2015)."},{"title3":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States"},{"title3":"Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease"},{"title3":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity"},{"title3":"Prevalence of nonalcoholic fatty liver disease in the United States: The third national health and nutrition examination survey, 1988-1994"},{"title3":"Hepatitis C infection in African Americans: its natural history and histological progression"},{"title3":"Increased overall mortality and liver related mortality in non-alcoholic fatty liver disease"},{"title3":"The Association Between Nonalcoholic Fatty Liver Disease and Noninvasively Assessed Fibrosis and Mortality: A 23 Years Prospective Population-Based Study [Abstract]"},{"title3":"Noninvasive fatty liver markers predict liver disease mortality in the U.S. population"},{"title3":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study"}]},{"title2":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study","References":[]},{"title2":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994","References":[]},{"title2":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","References":[]},{"title2":"Diabetes is a risk factor for the progression and prognosis of COVID-19","References":[{"title3":"Diabetes is a risk factor for the progression and prognosis of COVID-19"},{"title3":" https://www.cdc.gov/diabetes/basics/diabetes.html. Accessed April 10, 2020."},{"title3":"The immune system's involvement in obesity-driven type 2 diabetes"},{"title3":" https://bit.ly/2xjKnOF. Accessed April 10, 2020."},{"title3":"Severe outcomes among patients with coronavirus disease 2019-United States, February 12-March 16, 2020"}]},{"title2":"Obesity and COVID-19 severity in a designated hospital in Shenzhen, China","References":[]},{"title2":"Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study","References":[{"title3":"Liver injury during highly pathogenic human coronavirus infections"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series"},{"title3":"Chinese Clinical Guidance for COVID-19 Pheumonia Diagnosis and Treatment"},{"title3":"Low alanine aminotransferase cut-off for predicting liver outcomes; a nationwide population-based longitudinal cohort study"},{"title3":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease"},{"title3":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection"},{"title3":"Kupffer cell-dependent hepatitis occurs during influenza infection"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism"}]},{"title2":"ACG clinical guideline: evaluation of abnormal liver chemistries","References":[]},{"title2":"AASLD guidelines for treatment of chronic hepatitis B","References":[]},{"title2":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","References":[]},{"title2":"Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients","References":[]},{"title2":"Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores","References":[]},{"title2":"COVID-19 and the liver: little cause for concern","References":[{"title3":"Clinical characteristics of 2019 novel coronavirus infection in China"},{"title3":"Liver injury in COVID-19: management and challenges"},{"title3":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study"},{"title3":"Liver histology in ICU patients dying from sepsis: a clinico-pathological study"},{"title3":"Systemic viral infections and collateral damage in the liver"},{"title3":"Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis"},{"title3":"Simvastatin improves neutrophil function and clinical outcomes in pneumonia. A pilot randomized controlled clinical trial"},{"title3":"Evolution of the immune system in humans from infancy to old age"},{"title3":"Liver cirrhosis is independently associated with 90-day mortality in ARDS patients"}]},{"title2":"Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19","References":[{"title3":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis"},{"title3":"Kidney disease is associated with in-hospital death of patients with COVID-19"},{"title3":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis"},{"title3":"Coronavirus disease 2019 and prevalence of chronic liver disease: a meta-analysis"},{"title3":"Risk factors of critical &amp; mortal COVID-19 cases: a systematic literature review and meta-analysis"},{"title3":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group"},{"title3":"COVID-19: abnormal liver function tests"},{"title3":"Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)"},{"title3":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America"},{"title3":"Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS)"},{"title3":"A principal component analysis is conducted for a case series quality appraisal checklist"},{"title3":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials"},{"title3":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses"},{"title3":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study"},{"title3":"Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series"},{"title3":"Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China"},{"title3":"Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia"},{"title3":"A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias"},{"title3":"Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records"},{"title3":"Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China"},{"title3":"The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury"},{"title3":"Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: a retrospective single center analysis"},{"title3":"Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu province: a multicenter descriptive study"},{"title3":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series"},{"title3":"Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression"},{"title3":"Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China"},{"title3":"Clinical progression of patients with COVID-19 in Shanghai, China"},{"title3":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China"},{"title3":"Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China"},{"title3":"Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan"},{"title3":"Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at hospital admission in Shenzhen, China"},{"title3":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment"},{"title3":"Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center"},{"title3":"Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study"},{"title3":"Analysis of 92 deceased patients with COVID-19"},{"title3":"Epidemiologic and clinical characteristics of 26 cases of COVID-19 arising from patient-to-patient transmission in Liaocheng, China"},{"title3":"Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha"},{"title3":"Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19"},{"title3":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study"},{"title3":"Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis"},{"title3":"Clinical and immunological features of severe and moderate coronavirus disease 2019"},{"title3":"Coronavirus disease 2019 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan, People's Republic of China"},{"title3":"The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19"},{"title3":"Clinical characteristics of patients hospitalized with coronavirus disease, Thailand"},{"title3":"A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults"},{"title3":"Clinical and CT features of early stage patients with COVID- 19: a retrospective analysis of imported cases in Shanghai, China"},{"title3":"Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China"},{"title3":"Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients"},{"title3":"A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China"},{"title3":"Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study"},{"title3":"Clinical and virological data of the first cases of COVID-19 in Europe: a case series"},{"title3":"Clinical features of COVID-19-related liver damage"},{"title3":"Evaluation of hepatic enzymes changes and association with prognosis in COVID-19 patients"},{"title3":"Clinical features and treatment of COVID-19 patients in northeast Chongqing"},{"title3":"Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms"},{"title3":"Evolution of CT findings in patients with mild COVID-19 pneumonia"},{"title3":"Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan, China"},{"title3":"Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area"},{"title3":"Clinical and computed tomographic (CT) images characteristics in the patients with COVID-19 infection: What should radiologists need to know?"},{"title3":"Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia"},{"title3":"Clinical and transmission characteristics of covid-19 - a retrospective study of 25 cases from a single thoracic surgery department"},{"title3":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area"},{"title3":"Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19"},{"title3":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China"},{"title3":"Covid-19 in critically ill patients in the Seattle region - case series"},{"title3":"Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China"},{"title3":"Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional multicenter study"},{"title3":"Sixty-eight consecutive patients assessed for COVID-19 infection: Experience from a UK Regional infectious diseases Unit"},{"title3":"Clinical and autoimmune characteristics of severe and critical cases of COVID-19"},{"title3":"Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City, Henan Province"},{"title3":"Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection"},{"title3":"Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan, China"},{"title3":"Epidemiological and clinical features of 125 hospitalized patients with COVID-19 in Fuyang, Anhui, China"},{"title3":"Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings"},{"title3":"Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China"},{"title3":"Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China"},{"title3":"Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury"},{"title3":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan"},{"title3":"Clinical features of 85 fatal cases of COVID-19 From Wuhan: a retrospective observational study"},{"title3":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial"},{"title3":"Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients"},{"title3":"Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19"},{"title3":"Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China"},{"title3":"SARS-CoV-2 viral load in clinical samples of critically ill patients"},{"title3":"Diabetes is a risk factor for the progression and prognosis of COVID-19"},{"title3":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study"},{"title3":"Baseline Characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy"},{"title3":"Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China"},{"title3":"SARS-CoV-2 infection in children"},{"title3":"Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia"},{"title3":"Detection of Covid-19 in children in early january 2020 in Wuhan, China"},{"title3":"Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study"},{"title3":"A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features"},{"title3":"Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults"},{"title3":"Novel coronavirus infection in children outside of Wuhan, China"},{"title3":"Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding"},{"title3":"Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China"},{"title3":"Clinical characteristics of children with coronavirus disease 2019 in Hubei, China"},{"title3":"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study"},{"title3":"Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study"},{"title3":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore"},{"title3":"Incidence of adverse drug reactions in covid-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System"},{"title3":"Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019"},{"title3":"Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19"},{"title3":"Compassionate use of remdesivir for patients with severe Covid-19"},{"title3":"Liver injury is associated with severe Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies"},{"title3":"AGA Institute rapid review of the GI and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19"},{"title3":"COVID-19, MERS and SARS with concomitant liver injury-systematic review of the existing literature"},{"title3":"Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID- 19: a systematic review and meta-analysis"},{"title3":"The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: a systematic review and meta-analysis"},{"title3":"Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis"},{"title3":"COVID-19 and Liver dysfunction: a systematic review and meta-analysis of retrospective studies"},{"title3":"Liver injury during highly pathogenic human coronavirus infections"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"A pathological report of three COVID-19 cases by minimal invasive autopsies"},{"title3":"COVID-19: consider cytokine storm syndromes and immunosuppression"},{"title3":"Novel coronavirus pneumonia-related liver injury: etiological analysis and treatment strategy"},{"title3":"Endothelial cell infection and endotheliitis in COVID-19"},{"title3":"Liver and COVID 19 infection: a very preliminary lesson learnt from histological post-mortem findings in 48 patients"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19"},{"title3":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2"},{"title3":"Activation of the alternate renin-angiotensin system correlates with the clinical status in human cirrhosis and corrects post liver transplantation"},{"title3":"Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2"},{"title3":"Review article: COVID-19 and liver disease - what we know on 1st May 2020"},{"title3":"COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy"},{"title3":"COVID-19 in solid organ transplant recipients: initial report from the US epicenter"},{"title3":"Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet"}]},{"title2":"Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)","References":[{"title3":"Coronavirus disease (COVID-19) Situation Report - 113. Data as received by WHO from national authorities. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200512-covid-19-sitrep-113.pdf?sfvrsn=feac3b6d_2."},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies"},{"title3":"Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2"},{"title3":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa"},{"title3":"Xie H, Zhao J, Lian N, et al. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int. 2020 (online ahead of print)"},{"title3":"Liver injury in COVID-19: management and challenges"},{"title3":"Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver damage. medRxiv. 10.1101/2020.02.26.20026971"},{"title3":"Characteristics and mechanism of liver injury in 2019 coronavirus disease"},{"title3":"COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies"},{"title3":"Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies"},{"title3":"D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020 (online ahead of print)"},{"title3":"Fast, faster, and fastest: science on the run during COVID-19 drama:do not forget the liver"},{"title3":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease"},{"title3":"The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients"},{"title3":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance"},{"title3":"Acute-on-chronic liver failure"},{"title3":"Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. WHO Interim guidance. COVID-19: Laboratory and diagnosis. 2020. https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117."},{"title3":"Clinical management of COVID-19. WHO interim guidance. COVID-19: Clinical care. 2020. https://www.who.int/publications/i/item/clinical-management-of-covid-19."},{"title3":"Obesity and impaired metabolic health in patients with COVID-19"},{"title3":"Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis"},{"title3":"Implication of non- alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis"},{"title3":"Zhang Y, Zheng L, Liu L, et al. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan City, China. Liver Int. 2020 (online ahead of print)"},{"title3":"The pathogenesis and treatment of the 'cytokine storm' in COVID-19"},{"title3":"COVID-19: abnormal liver function tests"},{"title3":"Longitudinal association between markers of liver injury and mortality in COVID-19 in China"},{"title3":"Drug-induced liver injury: recent advances in diagnosis and risk assessment"},{"title3":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update"}]}]},{"title1":"Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease","References":[{"title2":"WHO characterizes COVID-19 as a pandemic","References":[]},{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia."},{"title3":"Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2."},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"First case of 2019 novel Coronavirus in the United States."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome."},{"title3":"A preventive and control strategy for COVID-19 infection: an experience from a Third-Tier Chinese City."},{"title3":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies."},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China."},{"title3":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2."},{"title3":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics."},{"title3":"Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia."},{"title3":"On the use of corticosteroids for 2019-nCoV pneumonia."},{"title3":"Comprehensive analysis of drugs to treat SARSCoV2 infection: mechanistic insights into current COVID19 therapies (Review)."},{"title3":"The role of telemedicine during the COVID-19 epidemic in China-experience from Shandong province."},{"title3":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial."},{"title3":"Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia."},{"title3":"Flattening the COVID-19 curve with natural killer cell based immunotherapies."},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."},{"title3":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event."},{"title3":"Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China."},{"title3":"Spatio-temporal metabolokinetics and efficacy of human placenta-derived mesenchymal stem/stromal cells on mice with refractory Crohn's-like enterocutaneous fistula."},{"title3":"High-efficient generation of VCAM-1(+) mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice."},{"title3":"Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease."},{"title3":"JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia."},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome."},{"title3":"Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review."},{"title3":"Three emerging coronaviruses in two decades."},{"title3":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future."},{"title3":"Coronaviruses - drug discovery and therapeutic options."},{"title3":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."},{"title3":"Acute respiratory distress syndrome: the Berlin Definition."},{"title3":"Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference."},{"title3":"Eicosanoid storm in infection and inflammation."},{"title3":"Decoding the enigma of antiviral crisis: does one target molecule regulate all?"}]},{"title2":"A new definition for metabolic associated fatty liver disease: an international expert consensus statement","References":[]},{"title2":"The crosstalk between hypoxia and innate immunity in the development of obesity-related nonalcoholic fatty liver disease","References":[{"title3":"Nonalcoholic fatty liver disease"},{"title3":"The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease"},{"title3":"The global NAFLD epidemic"},{"title3":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults"},{"title3":"Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013"},{"title3":"The global obesity pandemic: shaped by global drivers and local environments"},{"title3":"Obesity-associated liver disease"},{"title3":"Obesity and respiratory diseases"},{"title3":"Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens"},{"title3":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008"},{"title3":"Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese"},{"title3":"Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis"},{"title3":"Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease"},{"title3":"Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance"},{"title3":"Risk factors for obstructive sleep apnea in adults"},{"title3":"Obstructive sleep apnea syndrome in the so paulo epidemiologic sleep study"},{"title3":"Increased prevalence of sleep-disordered breathing in adults"},{"title3":"Intermittent hypoxemia and OSA: implications for comorbidities"},{"title3":"High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia"},{"title3":"Chronic intermittent hypoxia aggravates intrahepatic endothelial dysfunction in cirrhotic rats"},{"title3":"HIF-1alpha and HIF-2alpha are critically involved in hypoxia-induced lipid accumulation in hepatocytes through reducing PGC-1alpha-mediated fatty acid beta-oxidation"},{"title3":"Hepatocyte-specific hypoxia-inducible factor-1alpha is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice"},{"title3":"Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN"},{"title3":"Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver"},{"title3":"Chronic intermittent hypoxia predisposes to liver injury"},{"title3":"Oxygen sensing, homeostasis, and disease"},{"title3":"HIF transcription factors, inflammation, and immunity"},{"title3":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension"},{"title3":"Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology"},{"title3":"An essential role for p300/CBP in the cellular response to hypoxia"},{"title3":"Hypoxia and inflammation"},{"title3":"Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha "},{"title3":"The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion"},{"title3":"Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia"},{"title3":"Hypoxia induces dysregulation of lipid metabolism in HepG2 cells via activation of HIF-2alpha "},{"title3":"Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism"},{"title3":"Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1"},{"title3":"Hypoxia-inducible factor 2 regulates hepatic lipid metabolism"},{"title3":"Hypoxia-inducible transcription factor 2alpha promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis"},{"title3":"Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia"},{"title3":"HIF-1alpha induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice"},{"title3":"Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes"},{"title3":"Vascular and hepatic impact of short-term intermittent hypoxia in a mouse model of metabolic syndrome"},{"title3":"Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes"},{"title3":"A liver Hif-2alpha-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition"},{"title3":"The role of hypoxia inducible factor-1 in hepatocellular carcinoma"},{"title3":"The impact of hypoxia in hepatocellular carcinoma metastasis"},{"title3":"HIFs, angiogenesis, and cancer"},{"title3":"Tumor necrosis factor alpha: a key component of the obesity-diabetes link"},{"title3":"T-ing up inflammation in fat"},{"title3":"Regulatory T cells in obesity: the leptin connection"},{"title3":"The hypoxia-inducible factor pathway in adipocytes: the role of HIF-2 in adipose inflammation and hypertrophic cardiomyopathy"},{"title3":"Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity"},{"title3":"Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity"},{"title3":"Adipose tissue vascularization: its role in chronic inflammation"},{"title3":"Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation"},{"title3":"Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice"},{"title3":"Adipose tissue oxygenation: effects on metabolic function"},{"title3":"Metabolic signatures of human adipose tissue hypoxia in obesity"},{"title3":"Deletion of hypoxia-inducible factor-1alpha in adipocytes enhances glucagon-like peptide-1 secretion and reduces adipose tissue inflammation"},{"title3":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease"},{"title3":"Obesity, inflammation, and insulin resistance"},{"title3":"Insulin resistance, inflammation, and non-alcoholic fatty liver disease"},{"title3":"Toll-like receptor 4 polymorphisms and atherogenesis"},{"title3":"Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis"},{"title3":"Causes and metabolic consequences of fatty liver"},{"title3":"The role of pattern-recognition receptors in innate immunity: update on toll-like receptors"},{"title3":"Toll-like receptors: critical proteins linking innate and acquired immunity"},{"title3":"Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice"},{"title3":"Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice"},{"title3":"Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice"},{"title3":"Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis"},{"title3":"Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4"},{"title3":"Metabolie syndrome and altered gut microbiota in mice lacking toll-like receptor 5"},{"title3":"Pathogen recognition and innate immunity"},{"title3":"LPS/TLR4 signal transduction pathway"},{"title3":"Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes"},{"title3":"Endotoxemia is associated with an increased risk of incident diabetes"},{"title3":"Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis"},{"title3":"Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model"},{"title3":"Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers"},{"title3":"Metabolic endotoxemia initiates obesity and insulin resistance"},{"title3":"Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies"},{"title3":"A high-fat diet is associated with endotoxemia that originates from the gut"},{"title3":"Endotoxin-mediated hepatic lipid accumulation during parenteral nutrition in rats"},{"title3":"Hepatic steatosis after intestinal bypass:prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition"},{"title3":"Toll-like receptor 4-dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury"},{"title3":"C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet"},{"title3":"Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors"},{"title3":"Reciprocal modulation of toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids"},{"title3":"Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4"},{"title3":"TLR4 links innate immunity and fatty acid-induced insulin resistance"},{"title3":"Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4"},{"title3":"Targeting gut flora to prevent progression of hepatocellular carcinoma"},{"title3":"IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis"},{"title3":"Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis"},{"title3":"Loss of hepatic NF-kappaB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation"},{"title3":"Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents"},{"title3":"Bacterial cell wall components regulate adipokine secretion from visceral adipocytes"},{"title3":"Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease"},{"title3":"Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice"},{"title3":"Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet"},{"title3":"A nonsense polymorphism (R392X) in TLR5 protects from obesity but predisposes to diabetes"},{"title3":"Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse"},{"title3":"Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice"},{"title3":"DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH"},{"title3":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis"},{"title3":"Steatohepatitis: a tale of two 'Hits'?"},{"title3":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis"},{"title3":"NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha "},{"title3":"Hypoxic stress up-regulates the expression of Toll-like receptor 4 in macrophages via hypoxia-inducible factor"},{"title3":"Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients"},{"title3":"Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome"}]},{"title2":"Nonalcoholic fatty liver disease is associated with decreased lung function","References":[{"title3":"Epidemiology of non-alcoholic fatty liver disease in China"},{"title3":"Recent concepts in non-alcoholic fatty liver disease"},{"title3":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis"},{"title3":"Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis"},{"title3":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis"},{"title3":"NAFLD: a multisystem disease"},{"title3":"Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study"},{"title3":"Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India"},{"title3":"Mechanisms linking obesity with cardiovascular disease"},{"title3":"Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study"},{"title3":"Reduced lung function is independently associated with increased risk of type 2 diabetes in Korean men"},{"title3":"Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study"},{"title3":"Impaired lung function is associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in middle-aged and elderly Chinese"},{"title3":"The association of non-alcoholic fatty liver disease with lung function: A survey design analysis using propensity score"},{"title3":"Association Between Pulmonary Function and Nonalcoholic Fatty Liver Disease in the NHANES III Study"},{"title3":"Relationship between non-alcoholic fatty liver disease and pulmonary function"},{"title3":"Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years"},{"title3":"Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension"},{"title3":"Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases"},{"title3":"Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses"},{"title3":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology"},{"title3":"Standardization of Spirometry, 1994 Update"},{"title3":"Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society"},{"title3":"Spirometric standards for healthy nonsmoking adults"},{"title3":"Normal predictive values of spirometry in Korean population"},{"title3":"Pulmonary function of Canadian Eskimos"},{"title3":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects"},{"title3":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association"},{"title3":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults"},{"title3":"Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007-2010"},{"title3":"Nonalcoholic fatty liver disease is associated with decreased lung function"},{"title3":"Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease"},{"title3":"The association of non-alcoholic fatty liver disease with lung function: A survey design analysis using propensity score"},{"title3":"Metabolic syndrome and Chronic Obstructive Pulmonary Disease (COPD): The interplay among smoking, insulin resistance and vitamin D"},{"title3":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis"},{"title3":"Lung function impairment and metabolic syndrome: the critical role of abdominal obesity"},{"title3":"Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm?"},{"title3":"Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity"},{"title3":"Nonalcoholic fatty liver disease"},{"title3":"Environmental exposures and systemic hypertension are risk factors for decline in lung function"},{"title3":"Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional study"},{"title3":"Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China"},{"title3":"Is cigarette smoking an independent risk factor or a cofactor for nonalcoholic fatty liver disease?"},{"title3":"Smoking is not associated with nonalcoholic fatty liver disease"},{"title3":"Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis"},{"title3":"Associations between smoking and body weight in the US population: analysis of NHANES II"},{"title3":"Philip Morris toxicological experiments with fresh sidestream smoke: more toxic than mainstream smoke"},{"title3":"Association between cigarette smoking and metabolic syndrome: the Korea National Health and Nutrition Examination Survey"},{"title3":"Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver"},{"title3":"Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the Normative Aging Study"},{"title3":"Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease"},{"title3":"Insulin resistance is associated with decreased quadriceps muscle strength in nondiabetic adults aged &gt;or = 70 years"},{"title3":"Cross shift changes in lung function among bar and restaurant workers before and after implementation of a smoking ban"},{"title3":"Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10))"},{"title3":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis"},{"title3":"Adipose tissue, adipokines, and inflammation"},{"title3":"Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases"},{"title3":"Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins"}]},{"title2":"Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia","References":[]},{"title2":"Association between pulmonary function and nonalcoholic fatty liver disease in the NHANES III Study","References":[{"title3":"Nonalcoholic fatty liver disease"},{"title3":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994"},{"title3":"Fatty liver: a novel component of the metabolic syndrome"},{"title3":"Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups"},{"title3":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity"},{"title3":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population"},{"title3":"Extrahepatic complications of nonalcoholic fatty liver disease"},{"title3":"Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study"},{"title3":"Lung function impairment and metabolic syndrome: the critical role of abdominal obesity"},{"title3":"Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study"},{"title3":"Associations of measures of lung function with insulin resistance and type 2 diabetes: findings from the British Women's Heart and Health Study"},{"title3":"Vital capacity as a predictor of incident type 2 diabetes: the Atherosclerosis Risk in Communities study"},{"title3":"Spirometric reference values from a sample of the general US population"},{"title3":"Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study"},{"title3":"Forced vital capacity, airway obstruction and survival in a general population sample from the USA"},{"title3":"The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature"},{"title3":"Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study"},{"title3":"Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease"},{"title3":"Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease"},{"title3":"Abdominal obesity and respiratory function in men and women in the EPIC-Norfolk Study, United Kingdom"},{"title3":"Pulmonary function and abdominal adiposity in the general population"},{"title3":"Body composition and pulmonary function in the elderly: a 7-year longitudinal study"},{"title3":"Visceral fat adipokine secretion is associated with systemic inflammation in obese humans"},{"title3":"Visceral fat: a key mediator of steatohepatitis in metabolic liver disease"},{"title3":"Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue"},{"title3":"Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination"},{"title3":"Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver"},{"title3":"Prospective association between lung function and the incidence of diabetes - Findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-Up Study"},{"title3":"Relationship between non-alcoholic fatty liver disease and pulmonary function"},{"title3":"Gender and racial differences in nonalcoholic fatty liver disease"}]},{"title2":"Obesity and overweight in Asian people","References":[]},{"title2":"Metabolic syndrome:a new world-wide definition. A consensus statement from the International Diabetes Federation","References":[]},{"title2":"Obesity is a risk factor for greater COVID-19 severity","References":[]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]},{"title2":"COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies","References":[{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Liver injury in COVID-19: management and challenges"},{"title3":"Coronavirus disease 2019 (COVID-19) situation report-49"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"[2019-novel coronavirus infection in a three-month-old baby]"},{"title3":"[First case of severe childhood novel coronavirus pneumonia in China]"},{"title3":"[First case of 2019 novel coronavirus infection in children in Shanghai]"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series"},{"title3":"[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia"},{"title3":"[Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study]"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records"},{"title3":"Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV"},{"title3":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa"},{"title3":"Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection"},{"title3":"[Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia]"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"A review of acetaminophen poisoning"},{"title3":"The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member"},{"title3":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic"},{"title3":"Infection of neonatal mice with sindbis virus results in a systemic inflammatory response syndrome"},{"title3":"Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells"},{"title3":"Creg in hepatocytes ameliorates liver ischemia/reperfusion injury in a TAK1-dependent manner in mice"},{"title3":"An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury"},{"title3":"Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases"},{"title3":"Potential interventions for novel coronavirus in China: A systematic review"},{"title3":"The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)"},{"title3":"The clinical pathology of severe acute respiratory syndrome (SARS): a report from China"},{"title3":"[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]"},{"title3":"Potential natural compounds for preventing 2019-nCoV infection"},{"title3":"Glycyrrhizic acid in the treatment of liver diseases: literature review"},{"title3":"Structure of dimeric full-length human ACE2 in complex with B0ATI"},{"title3":"2019 novel coronavirus: where we are and what we know"}]},{"title2":"Visceral fat: a key mediator of steatohepatitis in metabolic liver disease","References":[]},{"title2":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation","References":[]}]},{"title1":"Clinical Features of Patients With COVID?19 With Nonalcoholic Fatty Liver Disease","References":[{"title2":"A novel coronavirus from patients with pneumonia in China, 2019","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition"},{"title3":"Importation and human-to-human transmission of a novel coronavirus in Vietnam"},{"title3":"2019 novel coronavirus (2019-nCoV) outbreak: a new challenge"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan"},{"title3":"Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China"},{"title3":"Novel Wuhan (2019-nCoV) coronavirus"},{"title3":"Severe acute respiratory syndrome coronavirus phylogeny: toward consensus"},{"title3":"Diagnosis and treatment of new coronavirus pneumonia (trial version 7) [J / OL]. Tianjin J Tradit Chin Med. 2020;1-5. http://kns.cnki.net/kcms/detail/12.1349.R.20200304.1638.006.html. Accessed 3 June 2020."},{"title3":"Clinical outcome of standardized oxygen therapy nursing strategy in COVID-19"},{"title3":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study"},{"title3":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission"},{"title3":"Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus"},{"title3":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection"},{"title3":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways"},{"title3":"Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome"},{"title3":"Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV"},{"title3":"Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients"},{"title3":"Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study"},{"title3":"C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early"},{"title3":"Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study"},{"title3":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China"},{"title3":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Human ipsc-derived cardiomyocytes are susceptible to Sars-Cov-2 infection"},{"title3":"Cardiovascular complications in COVID-19"},{"title3":"COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?"},{"title3":"Endothelial cell infection and endotheliitis in COVID-19"}]},{"title2":"Severe acute respiratory syndrome-related coronavirus: the species and its viruses - a statement of the Coronavirus Study Group","References":[]},{"title2":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","References":[{"title3":"Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance"},{"title3":"MERS, SARS and other coronaviruses as causes of pneumonia"},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score"},{"title3":"Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus"},{"title3":"Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human"},{"title3":"Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation"},{"title3":"Evidence for camel-to-human transmission of MERS coronavirus"},{"title3":"Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history"},{"title3":"Origin and evolution of pathogenic coronaviruses"},{"title3":"Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin"},{"title3":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for the risk of human transmission"},{"title3":"Wuhan coronavirus has strong ability to infect humans. Press release"},{"title3":"From SARS to MERS, thrusting coronaviruses into the spotlight"},{"title3":"Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis"},{"title3":"Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection"},{"title3":"Sexual dimorphism in innate immunity"},{"title3":"Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections"},{"title3":"Clinical findings in 111 cases of influenza A (H7N9) virus infection"},{"title3":"Clinical features of three avian influenza H7N9 virus-infected patients in Shanghai"},{"title3":"T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV"}]},{"title2":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","References":[]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]},{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia."},{"title3":"Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2."},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"First case of 2019 novel Coronavirus in the United States."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome."},{"title3":"A preventive and control strategy for COVID-19 infection: an experience from a Third-Tier Chinese City."},{"title3":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies."},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China."},{"title3":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2."},{"title3":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics."},{"title3":"Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia."},{"title3":"On the use of corticosteroids for 2019-nCoV pneumonia."},{"title3":"Comprehensive analysis of drugs to treat SARSCoV2 infection: mechanistic insights into current COVID19 therapies (Review)."},{"title3":"The role of telemedicine during the COVID-19 epidemic in China-experience from Shandong province."},{"title3":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial."},{"title3":"Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia."},{"title3":"Flattening the COVID-19 curve with natural killer cell based immunotherapies."},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."},{"title3":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event."},{"title3":"Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China."},{"title3":"Spatio-temporal metabolokinetics and efficacy of human placenta-derived mesenchymal stem/stromal cells on mice with refractory Crohn's-like enterocutaneous fistula."},{"title3":"High-efficient generation of VCAM-1(+) mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice."},{"title3":"Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease."},{"title3":"JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia."},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome."},{"title3":"Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review."},{"title3":"Three emerging coronaviruses in two decades."},{"title3":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future."},{"title3":"Coronaviruses - drug discovery and therapeutic options."},{"title3":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."},{"title3":"Acute respiratory distress syndrome: the Berlin Definition."},{"title3":"Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference."},{"title3":"Eicosanoid storm in infection and inflammation."},{"title3":"Decoding the enigma of antiviral crisis: does one target molecule regulate all?"}]},{"title2":"Liver injury in COVID-19: management and challenges","References":[{"title3":"The cytokine storm and COVID-19"},{"title3":"Kidney diseases and COVID-19 infection: causes and effect, supportive therapeutics and nutritional perspectives"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"COVID-19 and liver disease"},{"title3":"COVID-19 and the liver"},{"title3":"Liver Dysfunction Is Associated with Long-Term Mortality in Septic Shock"},{"title3":"Review article: COVID-19 and liver disease-what we know on 1st May 2020"},{"title3":"Gastrointestinal and liver manifestations in patients with COVID-19"},{"title3":"Liver diseases in COVID-19: Etiology, treatment and prognosis"},{"title3":"COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies"},{"title3":"Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis"},{"title3":"Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis"},{"title3":"A Case Series of Children With 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features"},{"title3":"Clinical characteristics of 82 cases of death from COVID-19"},{"title3":"Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort"},{"title3":"Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding"},{"title3":"SARS-CoV-2 Infection in Children"},{"title3":"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study"},{"title3":"Clinical Features of COVID-19-Related Liver Functional Abnormality"},{"title3":"Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China"},{"title3":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area"},{"title3":"Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series"},{"title3":"Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China"},{"title3":"Liver tests abnormalities in COVID-19: trick or treat?"},{"title3":"Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic"},{"title3":"Health Status of Patients Who Underwent Liver Transplantation During the Coronavirus Outbreak at a Large Center in Milan, Italy"},{"title3":"COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission"},{"title3":"COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract"},{"title3":"Liver injury in COVID-19: management and challenges"},{"title3":"Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease"},{"title3":"Coronavirus infections and immune responses"},{"title3":"Apoptosis: a mechanism of acute and chronic liver injury"},{"title3":"SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases"},{"title3":"Proteomics. Tissue-based map of the human proteome"},{"title3":"COVID-19 in a designated infectious diseases hospital outside Hubei Province, China"},{"title3":"Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)"},{"title3":"A literature review for the mechanisms of stress-induced liver injury"},{"title3":"Mechanisms and treatment of organ failure in sepsis"},{"title3":"Liver - guardian, modifier and target of sepsis"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"},{"title3":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase"},{"title3":"The emerging role of ACE2 in physiology and disease"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor"},{"title3":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein"},{"title3":"Human neutralizing antibodies elicited by SARS-CoV-2 infection"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes"},{"title3":"The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects"},{"title3":"A phase I trial of intravenous interleukin-6 in patients with advanced cancer"},{"title3":"Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells"},{"title3":"Systemic inflammation as fuel for acute liver injury in COVID-19"},{"title3":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality"},{"title3":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?"},{"title3":"Liver injury during highly pathogenic human coronavirus infections"},{"title3":"SARS-CoV-2: a storm is raging"},{"title3":"In the eye of the COVID-19 cytokine storm"},{"title3":"Viral and host factors related to the clinical outcome of COVID-19"},{"title3":"Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)"},{"title3":"Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China"},{"title3":"Use of lactate dehydrogenase to evaluate the anti-viral activity against influenza A virus"},{"title3":"Lactate dehydrogenase leakage as a marker for apoptotic cell degradation induced by influenza virus infection in human fetal membrane cells"},{"title3":"Adipokines: molecular links between obesity and atheroslcerosis"},{"title3":"A new perspective on C-reactive protein in H7N9 infections"},{"title3":"C-reactive protein as a biomarker of severe H1N1 influenza"},{"title3":"Cognitive decline in Parkinson disease"},{"title3":"Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Digestive Manifestations in Patients Hospitalized With Coronavirus Disease 2019"},{"title3":"Effect of Gastrointestinal Symptoms in Patients With COVID-19"},{"title3":"Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study"},{"title3":"AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19"},{"title3":"Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study"},{"title3":"Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19)"},{"title3":"COVID-19 and liver injury: where do we stand?"},{"title3":"Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection"},{"title3":"Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China"},{"title3":"Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement"},{"title3":"COVID-19: Abnormal liver function tests"},{"title3":"Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19"},{"title3":"Hepatic manifestations of COVID-19"},{"title3":"Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies"},{"title3":"Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis"},{"title3":"Acute Liver Failure in a COVID-19 Patient Without any Preexisting Liver Disease"},{"title3":"Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study"},{"title3":"Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19"},{"title3":"Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study"},{"title3":"Gastrointestinal and Hepatic Manifestations of COVID-19: Evolving Recognition and Need for Increased Understanding in Vulnerable Populations"},{"title3":"Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study"},{"title3":"COVID-19 in solid organ transplant recipients: A single-center case series from Spain"},{"title3":"COVID-19 in solid organ transplant recipients: Initial report from the US epicenter"},{"title3":"COVID-19 in solid organ transplantation patients: A systematic review"},{"title3":"Tocilizumab and liver injury in patients with COVID-19"},{"title3":"A Novel Coronavirus from Patients with Pneumonia in China, 2019"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor"},{"title3":"A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?"},{"title3":"Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19"},{"title3":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19"},{"title3":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir"},{"title3":"Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study"},{"title3":"Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives"},{"title3":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies"},{"title3":"The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design"},{"title3":"Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms"},{"title3":"Remdesivir for the Treatment of Covid-19 - Final Report"},{"title3":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19"},{"title3":"Liver injury in remdesivir-treated COVID-19 patients"},{"title3":"Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019"},{"title3":"Etiology and management of liver injury in patients with COVID-19"},{"title3":"Therapeutic Potential for Tetracyclines in the Treatment of COVID-19"},{"title3":"Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study"},{"title3":"Azithromycin augments rhinovirus-induced IFNbeta via cytosolic MDA5 in experimental models of asthma exacerbation"},{"title3":"Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 Levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis"},{"title3":"Azithromycin for COVID-19: More Than Just an Antimicrobial?"},{"title3":"Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective"},{"title3":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection"},{"title3":"First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19"},{"title3":"Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics"},{"title3":"Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine"},{"title3":"Liver Injury in COVID-19: Caution and Management"},{"title3":"Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient"},{"title3":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)"},{"title3":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review"},{"title3":"Tocilizumab and COVID-19"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report"},{"title3":"Polygalasaponin F treats mice with pneumonia induced by influenza virus"},{"title3":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study"},{"title3":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro"},{"title3":"The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells"},{"title3":"Ritonavir and Lopinavir Suppress RCE1 and CAAX Rab Proteins Sensitizing the Liver to Organelle Stress and Injury"},{"title3":"Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature"},{"title3":"Protective effect of bicyclol on lipopolysaccharide-induced acute lung injury in mice"},{"title3":"Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms"},{"title3":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study"},{"title3":"Current pharmacological treatments for COVID-19: What's next?"},{"title3":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity"},{"title3":"COVID-19: A review of the proposed pharmacological treatments"},{"title3":"Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis"},{"title3":"Chloroquine attenuates paraquat-induced lung injury in mice by altering inflammation, oxidative stress and fibrosis"},{"title3":"Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055"},{"title3":"The gut microbiota and host health: a new clinical frontier"},{"title3":"Contributions of the intestinal microbiome in lung immunity"},{"title3":"Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19"},{"title3":"Assessment of Renal and Hepatic Tissue-Protective Effects of N-Acetylcysteine via Ammonia Metabolism: A Prospective Randomized Study"},{"title3":"Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?"},{"title3":"Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke"},{"title3":"Could Vitamins Help in the Fight Against COVID-19?"},{"title3":"Role of vitamin E in nonalcoholic fatty liver disease"},{"title3":"Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths"},{"title3":"Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies"},{"title3":"Potential protection of vitamin C against liver-lesioned mice"},{"title3":"Zinc and COVID-19: Basis of Current Clinical Trials"},{"title3":"Zinc and liver disease"},{"title3":"Possibility of magnesium supplementation for supportive treatment in patients with COVID-19"},{"title3":"Magnesium and liver disease"},{"title3":"COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2"},{"title3":"Is copper beneficial for COVID-19 patients?"},{"title3":"Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats"},{"title3":"Corticosteroids in Acute Lung Injury: The Dilemma Continues"}]},{"title2":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","References":[]},{"title2":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","References":[]},{"title2":"Depression is associated with non-alcoholic fatty liver disease among adults in the United States","References":[]},{"title2":"Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016","References":[]},{"title2":"Elevated urinary bisphenol A levels are associated with non-alcoholic fatty liver disease among adults in the United States","References":[]},{"title2":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","References":[]},{"title2":"Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)","References":[]},{"title2":"The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis","References":[]},{"title2":"Clinical features of COVID-19-related liver functional abnormality","References":[{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2[J]"},{"title3":"WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Chinese Center for Disease Control and Prevention"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Diagnosis and treatment scheme of new coronavirus infected pneumonia. 2020"},{"title3":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China"},{"title3":"Presumed asymptomatic carrier transmission of COVID-19"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Pathogenetic mechanisms of severe acute respiratory syndrome"},{"title3":"Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases"},{"title3":"Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study"},{"title3":"A case of late presentation of darunavir-related cholestatic hepatitis"},{"title3":"Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity"},{"title3":"Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir"},{"title3":"Efficacies of lopinavir/ritonavir and arbidol in the treatment of novel coronavirus pneumonia"}]},{"title2":"Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection","References":[]},{"title2":"Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile","References":[]},{"title2":"Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study","References":[{"title3":"Liver injury during highly pathogenic human coronavirus infections"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series"},{"title3":"Chinese Clinical Guidance for COVID-19 Pheumonia Diagnosis and Treatment"},{"title3":"Low alanine aminotransferase cut-off for predicting liver outcomes; a nationwide population-based longitudinal cohort study"},{"title3":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease"},{"title3":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection"},{"title3":"Kupffer cell-dependent hepatitis occurs during influenza infection"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism"}]},{"title2":"Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients","References":[{"title3":"WHO characterizes COVID-19 as a pandemic"},{"title3":"Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)"},{"title3":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease"},{"title3":"A new definition for metabolic associated fatty liver disease: an international expert consensus statement"},{"title3":"Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease"},{"title3":"Metabolic syndrome:a new world-wide definition. A consensus statement from the International Diabetes Federation"},{"title3":"Metabolic syndrome and the lung"},{"title3":"COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies"}]},{"title2":"Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study","References":[]},{"title2":"Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study","References":[]},{"title2":"Hepatic steatosis index in the detection of fatty liver in patients with chronic hepatitis B receiving antiviral therapy","References":[{"title3":"Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes"},{"title3":"The global NAFLD epidemic"},{"title3":"Non-alcoholic fatty liver disease pathogenesis: the present and the future"},{"title3":"New trends on obesity and NAFLD in Asia"},{"title3":"Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B"},{"title3":"Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C"},{"title3":"Liver biopsy: is it still relevant?"},{"title3":"Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity"},{"title3":"The utility of radiological imaging in nonalcoholic fatty liver disease"},{"title3":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis"},{"title3":"Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance"},{"title3":"Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration"},{"title3":"Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling"},{"title3":"Liver fat content determined by magnetic resonance imaging and spectroscopy"},{"title3":"Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy"},{"title3":"Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection"},{"title3":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease"},{"title3":"A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B"},{"title3":"Study of hepatic steatosis index in patients with chronic HCV infection"},{"title3":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association"},{"title3":"Nonalcoholic fatty liver disease: definitions, risk factors, and workup"},{"title3":"Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis"},{"title3":"What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy"},{"title3":"Cirrhosis: diagnosis with sonographic study of the liver surface"},{"title3":"2015 Korean Guidelines for the Management of Dyslipidemia: executive summary (English translation)"},{"title3":"Liver biopsy"},{"title3":"Pain experienced during percutaneous liver biopsy"},{"title3":"The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation"},{"title3":"Computed tomography in nonalcoholic fatty liver disease: a useful tool for hepatosteatosis assessment?"},{"title3":"Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index"},{"title3":"Introduction of fast MR imaging in the assessment of hepatic steatosis"},{"title3":"Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B"},{"title3":"Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir"},{"title3":"Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B"},{"title3":"Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis: comparison with MRI-determined proton density fat fraction"},{"title3":"Accuracy of PDFF estimation by magnitude-based and complex-based MRI in children with MR spectroscopy as a reference"},{"title3":"Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis"},{"title3":"Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis"},{"title3":"Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?"},{"title3":"Platelets: no longer bystanders in liver disease"},{"title3":"Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials"},{"title3":"Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis"},{"title3":"Recent research trends and updates on nonalcoholic fatty liver disease"},{"title3":"Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial"}]},{"title2":"A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B","References":[]},{"title2":"Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view","References":[]},{"title2":"A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease","References":[]},{"title2":"Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury","References":[]},{"title2":"Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea","References":[]},{"title2":"AASLD guidelines for treatment of chronic hepatitis B","References":[]},{"title2":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","References":[{"title3":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations"},{"title3":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies"},{"title3":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity"},{"title3":"Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia"},{"title3":"Progress in the control of hepatitis B infection in the western Pacific region"},{"title3":"Chronic hepatitis B in Asia-new insights from the past decade"},{"title3":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection"},{"title3":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures"},{"title3":"Two decades of universal hepatitis B Vaccination IN Taiwan: impact and Implication for future strategies"},{"title3":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan"},{"title3":"Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination"},{"title3":"Recent trends in hepatitis B virus infection in the general Korean population"},{"title3":"Hepatitis B e antigen and the risk of hepatocellular carcinoma"},{"title3":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide"},{"title3":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008"},{"title3":"Epidemiology of viral hepatitis and hepatocellular carcinoma"},{"title3":"Dynamics and impact of perinatal transmission of hepatitis B virus in North India"},{"title3":"Prevalence, risk factors and virological profile of chronic hepatitis B virus infection in pregnant women in India"},{"title3":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update"},{"title3":"Management of hepatitis B: our practice and how it relates to the guidelines"},{"title3":"Virological and histological features of chronic hepatitis b virus infected asymptomatic patients with persistently normal ALT"},{"title3":"Management of patients with hepatitis B who require immunosuppressive therapy"},{"title3":"Differentiating acute viral hepatitis B from the first episode of exacerbation of chronic hepatitis B"},{"title3":"Higher efficacy of sequential therapy with Interferon alfa and lamivudine combination compared to Lamivudine monotherapy in HBeAg positive chronic hepatitis B patients: a controlled trial"},{"title3":"Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection"},{"title3":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels"},{"title3":"Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications"},{"title3":"Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study"},{"title3":"Updated definitions of healthy ranges for serum alanine aminotransferase levels"},{"title3":"Critical analysis of the immune tolerance phase of chronic HBV infection: natural history and diagnosis"},{"title3":"Treating immune-tolerant hepatitis B"},{"title3":"Natural history and disease progression in Chinese chronic hepatitis B patients in immunetolerant phase"},{"title3":"Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histological findings and outcome"},{"title3":"High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels"},{"title3":"Hepatitis B virus immuno tolerant patients: need to differentiate patients with or without liver disease"},{"title3":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death"},{"title3":"Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion"},{"title3":"Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis"},{"title3":"Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers"},{"title3":"Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F"},{"title3":"Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B"},{"title3":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study"},{"title3":"Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective"},{"title3":"Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia"},{"title3":"Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels"},{"title3":"Serial liver biopsies in blood donors with persistent HBs antigenaemia"},{"title3":"Long-term followup study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histological evaluation of 242 cases"},{"title3":"Chronic asymptomatic HBsAgs: histological abnormalities and diagnostic and prognostic value of serological markers of the HBV"},{"title3":"Liver biopsy in Chronic hepatitis B virus infected patients with normal ALT. Reply"},{"title3":"Spontaneous increase in ALT levels in asymptomatic chronic hepatitis B Virus Infected Patients"},{"title3":"The clinical significance of persistently normal ALT in chronic hepatitis B infection"},{"title3":"Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase"},{"title3":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level"},{"title3":"Natural history of chronic hepatitis B in Euro-Mediterranean and African countries"},{"title3":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B"},{"title3":"Management of hepatitis B: 2000-summary of a workshop"},{"title3":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012;50:42"},{"title3":"Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA"},{"title3":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus load"},{"title3":"Natural history of chronic hepatitis B infection: what we knew in 1981 and what we know in 2005"},{"title3":"Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study"},{"title3":"Quantitative serum HBVDNA levels during different stages of chronic hepatitis B infection"},{"title3":"Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B"},{"title3":"Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years"},{"title3":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection"},{"title3":"Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection"},{"title3":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B"},{"title3":"Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease"},{"title3":"Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers"},{"title3":"Viral load not serum ALT is the primary predictor of progression to cirrhosis in persons chronically infected with HBV: results from a long-term prospective study"},{"title3":"Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives"},{"title3":"Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men"},{"title3":"Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers"},{"title3":"Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the US"},{"title3":"Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to"},{"title3":"Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan"},{"title3":"Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976-2001"},{"title3":"Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma"},{"title3":"Hepatitis B virus genotype B isassociated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C"},{"title3":"Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations"},{"title3":"Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients"},{"title3":"HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects"},{"title3":"Clinical significance of genotypes and precore/basal core promoter mutations in HBV related chronic liver disease patients in North India"},{"title3":"Associations between hepatitis B virusmutations and the risk of hepatocellular carcinoma: a metaanalysis"},{"title3":"Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence"},{"title3":"Lamivudine for patients with chronic hepatitis B and advanced liver disease"},{"title3":"Report from a viral hepatitis policy forum on implementing the WHO framework for global action on viral hepatitis in North Asia"},{"title3":"Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California"},{"title3":"Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence"},{"title3":"Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden"},{"title3":"The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference"},{"title3":"Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale"},{"title3":"Liver cancer is the fastest increasing cause of cancer death in Australians"},{"title3":"Institute of medicine recommendations for the prevention and control of hepatitis B and C"},{"title3":"Hepatitis outreach network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities"},{"title3":"Hepatitis B: report of prevalence and access to healthcare among Chinese residents in Sheffield UK"},{"title3":"Barratt A, Irwig L, Glasziou P, Cumming RG, Raffle A, Hicks N, et al. Users' guides to the medical literature: XVII. How to use guidelines and recommendations about screening. Evidence-Based Medicine Working Group. JAMA 1999;281:2029-2034 (ref 112)"},{"title3":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load"},{"title3":"Risk and predictors of mortality associated with chronic hepatitis B infection"},{"title3":"A comprehensive screening and treatment model for reducing disparities in hepatitis B"},{"title3":"Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis"},{"title3":"Evaluation of the performance of four methods for detection of hepatitis B surface antigen and their application for testing 116,455 specimens"},{"title3":"Community-based hepatitis B screening: what works?"},{"title3":"Chronic hepatitis B: update 2009"},{"title3":"Epidemiology and prevention of hepatitis B virus infection"},{"title3":"Syringe exchange and risk of infection with hepatitis B and C viruses"},{"title3":"Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan"},{"title3":"Prevalence and factors associated with hepatitis B immunization and infection among men who have sex with men in Beijing, China"},{"title3":"Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment"},{"title3":"Screening for hepatitis B virus infection in pregnant women: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement"},{"title3":"Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis"},{"title3":"A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus"},{"title3":"Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation"},{"title3":"Progress toward prevention of transfusion-transmitted hepatitis B and hepatitis C infection:sub-Saharan Africa, 2000-2011"},{"title3":"Promoting national blood systems in developing countries"},{"title3":"Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis"},{"title3":"Diagnosis of hepatitis B virus infection through serological and virological markers"},{"title3":"Serological pattern &quot;anti-HBc alone&quot;: report on a workshop"},{"title3":"Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs"},{"title3":"Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis: an epidemiological study"},{"title3":"The risk of transmission ofhepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors"},{"title3":"De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population"},{"title3":"Review article: hepatitis B and liver transplantation"},{"title3":"Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study"},{"title3":"Perinatal transmission of hepatitis B virus: an Australian experience"},{"title3":"Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment"},{"title3":"The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease"},{"title3":"Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients"},{"title3":"Virological monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach"},{"title3":"Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the Cobas  AmpliPrep/Cobas  TaqMan  system"},{"title3":"Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study"},{"title3":"Exceeding the limits of liver histology markers"},{"title3":"Liver biopsy: the best, not gold standard"},{"title3":"Non-invasive prediction of forthcoming cirrhosis-related complications"},{"title3":"Non-invasive diagnosis of hepatitis B-virus related cirrhosis"},{"title3":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrsis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis"},{"title3":"Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan "},{"title3":"Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis"},{"title3":"Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B"},{"title3":"Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test"},{"title3":"On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients"},{"title3":"Analysis of discordance between transient elastography and liver biopsy for assessing liver fibrosis in chronic hepatitis B virus infection"},{"title3":"Non-invasive algorithm of enhamced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B"},{"title3":"Prognostic value of the combined use of transient 3elastography and fibrotest in patients with chronic hepatitis B"},{"title3":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma"},{"title3":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma"},{"title3":"Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia"},{"title3":"How to predict HCC development in patients with chronic B viral liver disease?"},{"title3":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B"},{"title3":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers"},{"title3":"Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection"},{"title3":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score"},{"title3":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load"},{"title3":"Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles"},{"title3":"Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients"},{"title3":"Predictive scores for hepatocellular carcinoma development in chronic hepatitis B virus infection:&quot;does one size fit all?&quot;"},{"title3":"Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir"},{"title3":"Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment"},{"title3":"Hepatocellular carcinoma: the point ofview of the hepatitis B virus"},{"title3":"A review of psychosocial issues in patients with chronic hepatitis B"},{"title3":"Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls"},{"title3":"Effects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China"},{"title3":"Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis"},{"title3":"Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease"},{"title3":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA"},{"title3":"Histological changes in liver tissue from patients with chronic hepatitis B and minimal increases in levels of alanine aminotransferase: a meta-analysis and systematic review"},{"title3":"Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels"},{"title3":"A 7-year study of lamivudine therapy for chronic hepatitis B virus e antigen-positive chronic hepatitis B patients in China"},{"title3":"Reduction of hepatitis B surface B antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy"},{"title3":"Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virological response in HBeAg-positive chronic hepatitis B"},{"title3":"Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study"},{"title3":"The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment"},{"title3":"Sustained response after a 2-year course of lamivudine treatment of hepatitis e antigen-negative chronic hepatitis B"},{"title3":"Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients"},{"title3":"Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients"},{"title3":" Chen CH, Lu SN, Hung CH, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Heaptol 2014;61(3):515-522 "},{"title3":"Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis"},{"title3":"Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance"},{"title3":"2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B"},{"title3":"Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients"},{"title3":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial"},{"title3":"Treatment of hepatitis B e antigen-positive chronic hepatitis B with telbivudine or adefovir: a randomized trial"},{"title3":"Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B"},{"title3":"The 1-4-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study"},{"title3":"Efficacy of entecavir switch therapy in chronic hepatitis B with incomplete virological response to telbivudine"},{"title3":"Telbivudine improves renal function in patients with chronic hepatitis B"},{"title3":"Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy"},{"title3":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B"},{"title3":"Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B"},{"title3":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years"},{"title3":"Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir"},{"title3":"Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance"},{"title3":"Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir"},{"title3":"Regression of cirrhosis during treatment with tenofovir disoproxil fumerate for chronic hepatitis B: a 5-year open-label follow-up study"},{"title3":"Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load"},{"title3":"Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients"},{"title3":"Randomized comparison of tenofovir disoproxil fumarate vs. emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B"},{"title3":"Tenofovir-associated Fanconi syndrome in patients with hepatitis B monoinfection"},{"title3":"Seven-year efficacy and safety of tretment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection"},{"title3":"HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D"},{"title3":"Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen"},{"title3":"Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients. An international multicenter cohort study"},{"title3":"Viral load and alanine aminotransferase correlate with serological response in chronic hepatitis B patients treated with entecavir"},{"title3":"Undetectable HBV DNA at month12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years"},{"title3":"Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment"},{"title3":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B"},{"title3":"Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy"},{"title3":" Bang SJ, Kim BG, Shin JW, et al. Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B. Dig Liver Dis. 2013;45(7):600-605"},{"title3":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection"},{"title3":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B paients: a propensity score analysis"},{"title3":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis"},{"title3":"Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response"},{"title3":"Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants"},{"title3":"Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir"},{"title3":"Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders"},{"title3":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients"},{"title3":"Treatment cessation of entecavir in hepatitis B e antigen-negative chronic hepatitis B Asian patients: a multicenter prospective study"},{"title3":"Lactic acidosis during telbivudine treatment for HBV: a case report and literature review"},{"title3":"Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B"},{"title3":"Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function"},{"title3":"Lactic acidosis during entecavir treatment in decompensated hepatitis B virus-related cirrhosis"},{"title3":"Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation"},{"title3":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy"},{"title3":"Randomized trial of virological response during up to two years of entecavir-adefovir combination therapy in multi-drug-refractory chronic hepatitis B virus patients"},{"title3":"Virological response and muscular adverse events during long-term clevudine therapy in chronic hepatitis B"},{"title3":"Long-term treatment efficacy and safety of clevudine therapy in naive patients with chronic hepatitis B"},{"title3":"Phase IIb multcentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B"},{"title3":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection"},{"title3":"A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B"},{"title3":"Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis"},{"title3":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B"},{"title3":"Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management"},{"title3":"Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy"},{"title3":"Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B"},{"title3":"Three-year efficacy and safety of tenofovir disoproxilfumarate treatment for chronic hepatitis B"},{"title3":"Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B"},{"title3":"Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B"},{"title3":"Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients"},{"title3":"Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir"},{"title3":"HBsAg kinetics in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate (TDF) for up to 4 years"},{"title3":"Relapse rate and associated-factor of recurrence after stopping NAs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients"},{"title3":"Long-term nucleos(t)ide analogue consolidation therapy reduces risk of relapse in chronic hepatitis B"},{"title3":"Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy"},{"title3":"The role of hepatitis B surface antigen quantification predict HBV reactivation after discontinuation of nucleos(t)ide analogs treatment in chronic hepatitis B patients with cirrhosis"},{"title3":"Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B"},{"title3":"Immunomodulator therapy of chronic hepatitis B"},{"title3":"Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis Be antigen-positive chronic hepatitis B"},{"title3":"Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China"},{"title3":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B"},{"title3":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial"},{"title3":"Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B"},{"title3":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b"},{"title3":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C"},{"title3":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B"},{"title3":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a"},{"title3":"Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B"},{"title3":"Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis"},{"title3":"Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B"},{"title3":"Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B"},{"title3":"Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients"},{"title3":"A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen negative chronic hepatitis B"},{"title3":"Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy"},{"title3":"A randomized controlled trial of sequential peginterferon-alpha and telbivudine or vice versa for 48 weeks in HBeAg-negative chronic hepatitis B"},{"title3":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)"},{"title3":"Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B: a multicentre randomized trial (ARES study)"},{"title3":"Jindal A, Kumar M, Sarin SK. Sequential therapy with tenofovir and pegylated interferon-alpha 2B versus tenofovir monotherapy in HBeAg positive chronic hepatitis B (CHB): an interim analysis. J Hepatol. 2014;60:S361-S522"},{"title3":"Marcellin P, et al. HBsAg loss with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PEG) in chronic hepatitis B (CHB): results of a global randomized controlled trial. American Association for the Study of Liver Diseases (AASLD) Liver Meeting, Boston, abstract 193, 2014"},{"title3":"Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversionin a subgroup of patients with chronic hepatitis B"},{"title3":"Chi H, Xie Q, Zhang N-P, Qi X, Liang C, Guo S, Guo Q, et al. Addition of peginterferon alfa-2b during long-term nucleos(t)ide analogue therapy increases HBeAg seroconversion and HBsAg decline:week 48 results from a multicenter randomized controlled trial (PEGON Study). Hepatology. 2014;60(S1):1106A"},{"title3":"Bourliere M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Pouget N, et al. HBsAg clearance after addition of 48 weeks of PEGIFN in HBeAg-negative CHB patients on nucleos(t)ide therapy with undetectable HBV DNA for at least one year: a multicenter randomized controlled phase III trial ANRS-HB06 PEGAN study: preliminary findings. Hepatology. 2014;60(S1):1094A"},{"title3":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa"},{"title3":"Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy"},{"title3":"HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated nterferon"},{"title3":"HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B"},{"title3":"Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B"},{"title3":"Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion"},{"title3":"Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B"},{"title3":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients"},{"title3":"Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-1257 (ref 524)"},{"title3":"Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients"},{"title3":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels"},{"title3":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a"},{"title3":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients"},{"title3":"Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, et al. Baseline quantitative hepatitis B core antibody titer alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or NAleos(t)ide analogues. Gut 2015. doi:10.1136/gutjnl-2014-308546"},{"title3":"Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy"},{"title3":"Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B"},{"title3":"New perspectives in the therapy of chronic hepatitis B"},{"title3":"IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B"},{"title3":"Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in HBeAg seropositive chronic hepatitis B patients"},{"title3":"Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther 2011;16:629-637 (ref 310)"},{"title3":"Tseng TC, Kao JH, Chen DS. Peginterferon alfa in the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2014. doi:10.1517/14712598.2014.907784"},{"title3":"Management of antiviral resistance in patients with chronic hepatitis B"},{"title3":"Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B"},{"title3":"Long-termentecavir therapy results in the reversal of fibrosis/cirrhosis and continuedhistological improvement in patients with chronic hepatitis B"},{"title3":"Incidence ofhepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review"},{"title3":"Virological suppression does notprevent the development of hepatocellular carcinoma in HBeAg-negativechronic hepatitis B patients with cirrhosis receiving oral antiviral(s)starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study"},{"title3":"Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhoticpatients in clinical practice"},{"title3":"Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viralcirrhotic patients: comparison between compensated and decompensated cirrhosis"},{"title3":"Spontaneous reactivation in chronic hepatitis B: patterns and natural history"},{"title3":"Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection"},{"title3":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study"},{"title3":"Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients"},{"title3":"Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients"},{"title3":"Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis"},{"title3":"Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients"},{"title3":"Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology"},{"title3":"Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease"},{"title3":"Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection"},{"title3":"Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis"},{"title3":"Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B"},{"title3":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease"},{"title3":"Hepatitis B virus core promoter mutations in children with multiple anti-HBe/HBeAg reactivations result in enhanced promoter activity"},{"title3":"Reactivation of chronic hepatitis B virus infection"},{"title3":"Influence of chronic HBV infection on pregnancy: a human model of maternofetal virus host interactions"},{"title3":"Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B eantigen seroconversion"},{"title3":"Patients with acute on chronic liver failure display &quot;sepsis-like&quot; immune paralysis"},{"title3":"The etiology of acute hepatitis in Taiwan: acute hepatitis superimposed upon HBsAg carrier state as the main etiology of acute hepatitis in areas with high HBsAg carrier rate"},{"title3":"Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections"},{"title3":"Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B"},{"title3":"Prognostic factors in severe exacerbation of chronic hepatitis B"},{"title3":"Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B"},{"title3":"Tsubota A, Arase Y, Suzuki Y, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2005;20:426-432 (ref 383)"},{"title3":"Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection"},{"title3":"Sun QF, Ding JG, Xu DZ, et al. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat 2009;16:464-470 (ref 377)"},{"title3":"Pretreatment HBsAg level and an early decrease in MELD score predict prognosis to lamivudine treatment for HBeAg negative acute-on-chronic liver failure"},{"title3":"Indicators and outcome of liver transplantation in acute liver decompensation after flares of hepatitis B"},{"title3":"Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure"},{"title3":"Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure"},{"title3":"A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure"},{"title3":"Different models in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure"},{"title3":"APACHE II score is superior to SOFA, CTP and MELD in predicting the short term mortality in patients with acute-on-chronic liver failure (ACLF)"},{"title3":"Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit"},{"title3":"Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study"},{"title3":"The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice"},{"title3":"Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection"},{"title3":"The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B"},{"title3":"Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis"},{"title3":"The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronicliver failure: a meta-analysis"},{"title3":"Short-term Entecavir therapy of chronic severe hepatitis B"},{"title3":"Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B"},{"title3":"Early entecavir treatment for chronic hepatitis B with severe acute exacerbation"},{"title3":"Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B"},{"title3":"Entecavir and lamivudine therapy for severe acute chronic hepatitis B"},{"title3":"Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure"},{"title3":"Entecavir vs lamivudine therapy for naive patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure"},{"title3":"On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study"},{"title3":"Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure"},{"title3":"Jindal A, Kumar M, Sarin SK. A prospective randomized controlled study to compare the efficacy of combined tenofovir plus telbuvidine versus tenofovir alone in patients with spontaneous reactivation of hepatitis B. J Viral Hepatitis 2015;22(Supplement S2):141-142"},{"title3":"Liver transplantation for acute-on-chronic liver failure"},{"title3":"Survival outcomes of right-lobe living donor transplantation for patients with high model for end stage liver disease scores"},{"title3":"Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure"},{"title3":"Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure"},{"title3":"Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure"},{"title3":"Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B"},{"title3":"Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma"},{"title3":"The changing pattern of epidemiology in hepatocellular carcinoma"},{"title3":"Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan"},{"title3":"Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C"},{"title3":"Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis"},{"title3":"Management of hepatocellular carcinoma: an update"},{"title3":"Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?"},{"title3":"Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)"},{"title3":"Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B"},{"title3":"The option of HBIG free prophylaxis against recurrent HBV"},{"title3":"Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence"},{"title3":"Hepatocellular carcinoma is associated withan increased risk of hepatitis B virus recurrence after liver transplantation"},{"title3":"Liver transplantation in European patients with the hepatitis B surface antigen"},{"title3":"Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxisagainst hepatitis B virus recurrence after liver transplantation: a systematic review"},{"title3":"Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis"},{"title3":"High geneticbarrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review"},{"title3":"Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin"},{"title3":"Prevention of hepatitis B virus reinfection in liver transplant recipients"},{"title3":"Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B followingliver transplantation"},{"title3":"Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: an open single-arm prospective study"},{"title3":"Impact of virological breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation"},{"title3":"A randomized study comparing lamivudine monotherapyafter a short course of hepatitis B immune globulin (HBIg) and lamivudine with longterm lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation"},{"title3":"Adherence tolamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitisB virus recurrence"},{"title3":"A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis"},{"title3":" Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Randomized trial of emtricitabine/tenofovirdisoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013;19:594-601"},{"title3":"Post-transplantationsequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin"},{"title3":"Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis"},{"title3":"Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results"},{"title3":"Combination lamivudine plus adefovir without HBIG is safe and effective prophylaxis against HBV recurrence inHBsAg+ liver transplant candidates"},{"title3":"Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B"},{"title3":"Living related liver transplantation for hepatitis B-related liverdisease without hepatitis B immune globulin prophylaxis"},{"title3":"Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin"},{"title3":"HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis"},{"title3":"Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence"},{"title3":"Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation"},{"title3":"Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplanthepatitis B virus prophylaxis?"},{"title3":"HIV-HBV coinfection:a global challenge"},{"title3":"Hepatitis B and human immunodeficiency virus coinfection"},{"title3":"HepatitisB and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort"},{"title3":"HIV-1, hepatitis B virus, and risk of liverrelated mortality in the Multicenter Cohort Study (MACS)"},{"title3":"Hepatitis C virus and human immunodeficiency virus coinfection in Spain"},{"title3":"Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS"},{"title3":"Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival"},{"title3":"Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiencyvirus: no evidence of faster progression to AIDS"},{"title3":"Hepatitis B virus (HBV) coinfection accelerates immunological progression in patients with primary HIV infection in an area of hyperendemicity for HBV infection"},{"title3":"Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters"},{"title3":"Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study"},{"title3":"The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state"},{"title3":"Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men"},{"title3":"Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic"},{"title3":"Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection"},{"title3":"Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy"},{"title3":"Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study"},{"title3":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV infected adults"},{"title3":"Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus"},{"title3":"The HBV drug entecavir :effects on HIV-1replication and resistance"},{"title3":"Selection of hepatitis B virus polymerasemutations in HIV coinfected patients treated with tenofovir"},{"title3":"Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions"},{"title3":"New paradigms for treating hepatitis B in HIV/HBV co-infected patients"},{"title3":"HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain"},{"title3":"HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance"},{"title3":"Immunizations in HIV-infected adults"},{"title3":"Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial"},{"title3":"Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection"},{"title3":"Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection"},{"title3":"Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis"},{"title3":"Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C"},{"title3":"Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients"},{"title3":"Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference"},{"title3":"Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients"},{"title3":"Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses"},{"title3":"Sustained HCV.clearance and increased HBsAgseroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up"},{"title3":"The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection"},{"title3":"Treatment of patients with dual hepatitis C and B by peginterferon alpha and ribavirin reduced risk of hepatocellular carcinoma and mortality"},{"title3":"Hepatitis delta virus"},{"title3":"Natural history andtreatment of chronic delta hepatitis"},{"title3":"Treatment options for hepatitis delta virus infection"},{"title3":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta:relevance of quantitative RT-PCR for follow-up"},{"title3":"Longterm benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis"},{"title3":"Long-term followup after Peg-IFNa2a-based therapy of chronic hepatitis delta"},{"title3":"Treatment of chronic hepatitis D with interferon alfa-2a"},{"title3":"Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials"},{"title3":"Standard and pegylated interferon therapy of HDVinfection: a systematic review and meta-analysis"},{"title3":"Entecavir treatment of chronic hepatitis D"},{"title3":"Treatment of chronic hepatitis d patients with pegylated interferon: a real world experience"},{"title3":"Abbas Z, Khan MA, Salih M, Jafri W, et al. Interferon alfa for chronic hepatitis D. Cochrane Database Syst Rev 2011;(12):CD006002"},{"title3":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor"},{"title3":"Human chimeric uPA mouse model to study hepatitis B and D virus interactions and preclinical drug evaluation"},{"title3":"Peginterferon plus adefovir versus either drug alone for hepatitis delta"},{"title3":"Chen GY, et al. Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir. J Formos Med Assoc 2013. doi:10.1016/j.jfma.2013.05.011"},{"title3":"Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtrictabine"},{"title3":"Quantitative longitudinal evaluations of hepatitis delta virus RNA andvhepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D"},{"title3":" CDC. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(RR-7):1-45"},{"title3":"CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50(RR-11)1-52"},{"title3":"Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure: estimates based on a model"},{"title3":"Hepatitis B and the infected health care worker: public safety at what cost?"},{"title3":"Management of hepatitis B virus infected health care workers based on HBV DNA levels"},{"title3":"Infection with hepatitis B virus after open heart surgery"},{"title3":"Transmission ofhepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control"},{"title3":"Transmission of hepatitis B with resultant restriction of surgical practice"},{"title3":"Hepatitis B infections after gynaecological surgery"},{"title3":"HBV DNA levels and transmission of hepatitis B by health care workers"},{"title3":"Transmission of hepatitis B virus from a surgeon to his patients during high-risk and low-risk surgical procedures during 4 years"},{"title3":"Transmission of HBV, HCV and HIV by infectious medical personnel:presentation of an overview"},{"title3":"Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students"},{"title3":"SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus"},{"title3":"JanssenHL, Schalm SW: prolonged antiviral therapy for hepatitis B virus-infected health careworkers: a feasible option to prevent work restriction without jeopardizing patient safety"},{"title3":"BEHoLD AI463022 Study Group: a comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B"},{"title3":"Comparison of tenofovir and entecavir in patients with chronic HBV infection"},{"title3":"Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy"},{"title3":"Management of hepatitis B during pregnancy"},{"title3":"Antiviral therapy for chronic hepatitis B in pregnancy"},{"title3":"Committee APRS. Antiretroviral Pregnancy Registry International. Interim Report for 1 January Through 31 JANUARY 2013. Wilmington, NC: Registry Coordinating Center; 2013 (online). http://www.APRegistry.com (2012)"},{"title3":"Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013;59:24-30 (ref 561)"},{"title3":"Prevention of vertical transmission of hepatitis B: an observational study"},{"title3":"Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis"},{"title3":"Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2014; 60(Suppl. S1):984A [(AASLD 2014) abstract]"},{"title3":"Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011;55:1215-1221 (ref 555)"},{"title3":"Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B Virus"},{"title3":"Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series"},{"title3":"Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice"},{"title3":"Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus"},{"title3":"Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection"},{"title3":"Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS12109 TEmAA Study, step 2"},{"title3":"Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers"},{"title3":"Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare"},{"title3":"Nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease"},{"title3":"Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children"},{"title3":"Extrahepatic manifestations of chronic viral hepatitis"},{"title3":"Free, &quot;small&quot; and IgG-associated &quot;large&quot; hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis"},{"title3":"IgA nephropathy and membranous nephropathy associated with hepatitis B surface antigenemia"},{"title3":"Role of hepatitis B virus infection in pathogenesis of IgA nephropathy"},{"title3":"Lamivudine in hepatitis B-associated membranous nephropathy"},{"title3":"Complete remission of hepatitis B virus-associated nephrotic syndrome from IgA nephropathy following peginterferon therapy"},{"title3":"Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis"},{"title3":"Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis"},{"title3":"Clinical features and outcomes in 348 patients with polyarteritis nodosa"},{"title3":"Epidemiology of systemic vasculitis"},{"title3":"Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome"},{"title3":"Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa"},{"title3":"Association between hepatitis B virus and essential mixed cryoglobulinemia"},{"title3":"Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers"},{"title3":"Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis"},{"title3":"Successful treatment of hepatitis B virus infection and related cryoglobulinaemic purpura with nuleoside/nucleotide analogues"},{"title3":"Hepatitis B: the pathway to recovery through treatment"},{"title3":"Arthritis in acute hepatitis and chronic active hepatitis. Pathology of the synovial membrane with evidence for the presence of Australia antigen in synovial membranes"},{"title3":"Dermatological manifestations in hepatitis B surface antigen carriers in east region of Turkey"},{"title3":"Gianotti-Crosti syndrome caused by acute hepatitis B virus genotype D infection"},{"title3":"Acute hepatitis B presenting as Guillain-Barre syndrome"},{"title3":"A rare case of acute hepatitis B virus infection causing Guillain-Barre syndrome"},{"title3":"Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy"},{"title3":"Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues"},{"title3":"Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients"},{"title3":"Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma"},{"title3":"Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma"},{"title3":"High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study"},{"title3":"Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids"},{"title3":"Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma"},{"title3":"Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection"},{"title3":"Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels"},{"title3":"Indefinite antiviral therapy may be required after surgical resection for hepatocellular carcinoma complicating chronic hepatitis B"},{"title3":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection"},{"title3":"Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma"},{"title3":"Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: a meta-analysis"},{"title3":"Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis"},{"title3":"Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection"},{"title3":"Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study"},{"title3":"Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis"},{"title3":"The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review"},{"title3":"Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis"},{"title3":"A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation"},{"title3":"Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis"},{"title3":"Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation"},{"title3":"U.N. General Assembly Document A/RES/44/25 (12 December 1989)"},{"title3":"Natural history of hepatitis B virus infection: pediatric perspective"},{"title3":"Corte CD, Nobili V, Comparcola D, Cainelli F, Vento S. Management of chronic hepatitis B in children: an unresolved issue. J Gastroenterol Hepatol 2014;29:912-919 (ref 634)"},{"title3":"Hepatitis B and C in children: current treatment and future strategies"},{"title3":"Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan"},{"title3":"Chronic hepatitis type B in childhood: longitudinal study of 35 cases"},{"title3":"Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B infection in childhood"},{"title3":"Long-term outcome in children with chronic hepatitis B: a 24-year observation period"},{"title3":"Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study"},{"title3":"Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins"},{"title3":"The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection"},{"title3":"Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expertpanel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition"},{"title3":"Predictors of virological response tolamivudine treatment in children with chronic hepatitis B infection"},{"title3":"Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-995 (ref 629)"},{"title3":"Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment"},{"title3":"Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger"},{"title3":"Long-term effect of alpha interferon in children with chronic hepatitis B"},{"title3":"Chronic hepatitis Binfection: long term comparison of children receiving interferon alpha and untreated controls"},{"title3":"Clinical trial of lamivudinein children with chronic hepatitis B"},{"title3":"Response to lamivudine in children with chronic hepatitis B virus infection"},{"title3":"Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon"},{"title3":"Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to &lt;18 years) with chronic hepatitis B"},{"title3":"Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronichepatitis B infection"},{"title3":"Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B"},{"title3":"Dynamics of hepatitis B virus clearance in chimpanzees"},{"title3":"The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response"},{"title3":"Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors"},{"title3":"Kinetics of acute hepatitis B virus infection in humans"},{"title3":"Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses"},{"title3":"Prognostic significance of quantitative HBsAg determination in acute hepatitis B. Partial report of a cooperative clinical study of the DFG-focus of &quot;virus hepatitis&quot;"},{"title3":"The serology of chronic hepatitis infection revisited"},{"title3":"Bilirubin, aspartate aminotransferase and platelet count score: a novel score for differentiating patients with chronic hepatitis B with acute flare from acute hepatitis B"},{"title3":"Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults"},{"title3":"Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults"},{"title3":"High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitis B"},{"title3":"Lamivudine treatment for acute severe hepatitis B: a pilot study"},{"title3":"A randomized controlled trial of lamivudine to treat acute hepatitis B"},{"title3":"The study of efficacy of lamivudine in patients with severe acute hepatitis B"},{"title3":"Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience"},{"title3":"Lamivudine treatment improves the prognosis of fulminant hepatitis B"},{"title3":"Lamivudine treatment is associated with improved survival in fulminant hepatitis B"},{"title3":"Hepatitis B associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae"},{"title3":"Acute hepatitis B: is antiviral therapy indicated? Two case reports"},{"title3":"Tenofovir treatment of the severe acute hepatitis B"},{"title3":"Tenofovir as rescue therapy following clinical failure to Lamivudine in severe acute hepatitis B"},{"title3":"Treatment with telbivudine for fulminant hepatitis B"},{"title3":"Hepatitis B virus reactivation associated with anti-neoplastic therapy"},{"title3":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy"},{"title3":"A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial"},{"title3":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy"},{"title3":"Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis"},{"title3":"Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma"},{"title3":"Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature"},{"title3":"Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy"},{"title3":"Viral hepatitis in solid organ transplantation other than liver"},{"title3":"Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs"},{"title3":"Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action"},{"title3":"Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis"},{"title3":"Kinetic and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy"},{"title3":"Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab"},{"title3":"Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma"},{"title3":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab"},{"title3":"Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study"},{"title3":"Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis"},{"title3":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study"},{"title3":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study"},{"title3":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B"},{"title3":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy"},{"title3":"Screening, prevention and treatment of viralhepatitis B reactivation in patients with haematological malignancies"},{"title3":"Prophylaxis and treatment of hepatitis B in immunocompromised patients"},{"title3":"Prophylaxis, diagnosis and therapy of hepatitis B virus infection:the German guideline"},{"title3":"Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoieticSCT"},{"title3":"Hepatitis B virus DNA viral load determination in hepatitis B surface antigen-negative Swiss blood donors"},{"title3":"Evidence for intrafamilial transmission of hepatitis B virus from sequence analysis of mutant HBV DNAs in two Chinese families"},{"title3":"Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization"},{"title3":"Virological factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers"},{"title3":"Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants"},{"title3":"Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report"},{"title3":"Viral hepatitis eradication in India by 2080:gaps, challenges and targets"},{"title3":"Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China"},{"title3":"Transfusion-transmitted hepatitis B virus infection"},{"title3":"Persistent viremia after recovery from self-limited acute hepatitis B"},{"title3":"Long-term histological and virological outcomes of acute self-limited hepatitis B"},{"title3":"HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma"},{"title3":"Occult HBV infection: a faceless enemy in liver cancer development"},{"title3":"Prevalence of occult hepatitis B virus infection in a general adult population in Korea"},{"title3":"Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice"},{"title3":"Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population"},{"title3":"Occult hepatitis B infection in blood donors"},{"title3":"Occult hepatitis B virus infection in a North American community-based population"},{"title3":"Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen"},{"title3":"Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma"},{"title3":"Huang FY, Wong DK, Seto WK, et al. Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. PLoS One 2014;9:e99028 (ref 715)"},{"title3":"Occult hepatitis B infection and HBV replicative activity in patients with cryptogeniccause of hepatocellular carcinoma"},{"title3":"Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence"},{"title3":"Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection"},{"title3":"Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals"},{"title3":"T cell responses and viral variability in blood donation candidates with occult hepatitis B infection"},{"title3":"Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese"},{"title3":"HLA-DP and gamma-interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection"},{"title3":"HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B"},{"title3":"Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients"},{"title3":"Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program"},{"title3":"Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis"},{"title3":"Hepatitis B virus serological and virological activities in blood donors with occult hepatitis B"},{"title3":"Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis"},{"title3":"Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely &quot;occult&quot;?"},{"title3":"Occult hepatitis B (OBH) in clinical settings"},{"title3":"Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens"},{"title3":"Virological analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus"},{"title3":"Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study"},{"title3":"Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis"},{"title3":"Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation"},{"title3":"Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)"},{"title3":"HBV induced carcinogenesis"},{"title3":"Hepatitis B: future curative strategies"},{"title3":"Sodium taurocholate cotransporting polypeptide is a functional receptorfor human hepatitis B and D virus"},{"title3":"Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP"},{"title3":"Efficientinhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein"},{"title3":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus"},{"title3":"Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes"},{"title3":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA"},{"title3":"An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases"},{"title3":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection"},{"title3":"Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly"},{"title3":"In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations"},{"title3":"http://www.drugdevelopment-technology.com/news/newsnovira-initiates-phase-Ia-trial-of-nvr-1221-totreat-chronic-hepatitis-B-infection-258446331.html. (Accessed 27 Jan 2015)"},{"title3":"beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity"},{"title3":"Treatment options beyond IFNalpha and NAs for chronic HBV infection: expectations for tomorrow"},{"title3":"The molecular basis of the failed immune response in chronic HBV: therapeutic implications"},{"title3":"Restored function of HBV-specific T cells after long term effective treatment with nucleos(t)ide analogues"},{"title3":"A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice"},{"title3":"A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance"},{"title3":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings"},{"title3":"Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection"},{"title3":"CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion"},{"title3":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice"},{"title3":"Engineering virus-specific T cells that target HBV-infected hepatocytes and hepatocellular carcinoma cell lines"},{"title3":"Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B"},{"title3":"Targeted delivery of interferon-a to hepatitis B virus-infected cells using T-cell receptor-like antibodies"},{"title3":"GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis b virus in chronically infected chimpanzees"},{"title3":"IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells"},{"title3":"Interleukin-18 inhibits hepatitis b virus replication in the livers of transgenic mice"},{"title3":"Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver"}]}]},{"title1":"Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study","References":[{"title2":"Trends in the burden of chronic liver disease among hospitalized US adults","References":[{"title3":"Underestimation of liver-related mortality in the United States"},{"title3":"Prevalence of alcoholic fatty liver disease among adults in the United States, 2001-2016"},{"title3":"Nonalcoholic fatty liver disease: a systematic review"},{"title3":"Epidemiology of chronic liver diseases in the USA in the past three decades"},{"title3":"Alcoholic liver disease epidemiology in the United States: a retrospective analysis of three United States databases"},{"title3":"Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study"},{"title3":"Rising inpatient encounters and economic burden for patients with nonalcoholic fatty liver disease in the USA"},{"title3":"Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database"},{"title3":"Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B"},{"title3":"Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study"},{"title3":"Increasing clinical and economic burden of nonalcoholic fatty liver disease among hospitalized adults in the United States"},{"title3":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008"},{"title3":"Increasing burden of hepatic encephalopathy among hospitalized adults: an analysis of the 2010-2014 National Inpatient Sample"},{"title3":"Increasing health care burden of chronic liver disease compared with other chronic diseases, 2004-2013"},{"title3":"Trends in chronic liver disease-related hospitalizations: a population-based study"},{"title3":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies"},{"title3":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013"},{"title3":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study"},{"title3":" CPI Inflation Calculator. Accessed September 29, 2019. https://data.bls.gov/cgi-bin/cpicalc.pl "},{"title3":"Adherence to methodological standards in research using the National Inpatient Sample"},{"title3":"Multiple imputation: a primer"},{"title3":"How can I deal with missing data in my study?"},{"title3":"Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents"},{"title3":"Burden of liver diseases in the world"},{"title3":"Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening"},{"title3":"OPTN/SRTR 2015 annual data report: liver"},{"title3":"Acute-on-chronic liver failure: an update"},{"title3":"Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation"},{"title3":"Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016"},{"title3":"Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans"},{"title3":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression"},{"title3":"Simple, effective, but out of reach? public health implications of HCV drugs"},{"title3":"A quality improvement initiative reduces 30-day rate of readmission for patients with cirrhosis"},{"title3":"Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis"},{"title3":"Development of quality measures in cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases"},{"title3":"An explicit quality indicator set for measurement of quality of care in patients with cirrhosis"},{"title3":"Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis"},{"title3":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings"},{"title3":"Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography"},{"title3":"Hospital readmissions among patients with decompensated cirrhosis"},{"title3":" Overweight and obesity. Accessed July 26, 2019. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight "},{"title3":" Adult overweight and obesity. Accessed July 26, 2019. https://www.cdc.gov/obesity/data/adult.html"},{"title3":" National diabetes statistics report. Accessed July 26, 2019. https://www.cdc.gov/diabetes/data/statistics/statistics-report.html"},{"title3":"Liver"},{"title3":"Diabetes is associated with clinical decompensation events in patients with cirrhosis"},{"title3":"Limitations of administrative databases"},{"title3":"National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008"},{"title3":"1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998-2009: a large population study"},{"title3":"Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis"}]},{"title2":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","References":[{"title3":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017"},{"title3":"The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization"},{"title3":"The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study"},{"title3":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis"},{"title3":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies"},{"title3":"All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study"},{"title3":"Treatment of patients with cirrhosis"},{"title3":"Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C"},{"title3":"Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis"},{"title3":"Review article: the reversibility of cirrhosis"},{"title3":"Liver cirrhosis"},{"title3":"Burden of liver diseases in the world"},{"title3":"Underestimation of liver-related mortality in the United States"},{"title3":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013"},{"title3":"Future treatments of cirrhosis"},{"title3":"Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes"},{"title3":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis"},{"title3":"Worldwide patterns and trends in mortality from liver cirrhosis, 1955 to 1990"},{"title3":"Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis"},{"title3":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017"},{"title3":"Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017"},{"title3":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017"},{"title3":"Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: a validation study"},{"title3":"Positive predictive value of International Classification of Diseases, 10th revision, codes for cirrhosis and its related complications"},{"title3":"Modeling causes of death: an integrated approach using CODEm"},{"title3":"Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017"},{"title3":"Health effects of overweight and obesity in 195 countries over 25 years"},{"title3":"Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016"},{"title3":"Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes"},{"title3":"Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe"},{"title3":"Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study"},{"title3":"Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study"},{"title3":"Liver cirrhosis in sub-Saharan Africa: neglected, yet important"},{"title3":"Alcoholic liver disease in Asia, Europe, and North America"},{"title3":"Global strategy to reduce the harmful use of alcohol"},{"title3":"The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference"},{"title3":"Chronic liver disease and cirrhosis mortality by state"},{"title3":"Liver cirrhosis in England:an observational study: are we measuring its burden occurrence correctly?"},{"title3":"Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications"},{"title3":"Viral hepatitis in the WHO South-East Asia Region"},{"title3":"Global hepatitis report, 2017"},{"title3":"The use of generic medications for hepatitis C"},{"title3":"Combating hepatitis B and C to reach elimination by 2030"},{"title3":"Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience"},{"title3":"Hepatitis elimination by 2030: progress and challenges"},{"title3":"The epidemiology of nonalcoholic steatohepatitis"},{"title3":"Nonalcoholic fatty liver disease risk factors in Latin American populations: current scenario and perspectives"}]},{"title2":"Burden of liver diseases in the world","References":[{"title3":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe"},{"title3":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis"},{"title3":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030"},{"title3":"Practice patterns in NAFLD and NASH: real life differs from published guidelines"},{"title3":"Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines"},{"title3":"Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging"},{"title3":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis"},{"title3":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology"},{"title3":"Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches"},{"title3":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with NASH and advanced fibrosis"},{"title3":"Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review"},{"title3":"Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease"},{"title3":"Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey Data"},{"title3":"NAFLD-the next global epidemic"},{"title3":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease"},{"title3":"Variables associated with inpatient and outpatient resource utilization among Medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis"},{"title3":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis"},{"title3":"Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation"},{"title3":"Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis"},{"title3":"Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study"},{"title3":"Cost-utility analysis of nonalcoholic steatohepatitis screening"},{"title3":"Burden of illness and economic model for patients with non-alcoholic steatohepatitis (NASH) in the United States"},{"title3":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?"},{"title3":"Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey"},{"title3":"The association between nonalcoholic fatty liver disease and cardiovascular disease outcomes"},{"title3":"Global epidemiology of nonalcoholic fatty liver disease:meta-analytic assessment of prevalence, incidence, and outcomes"},{"title3":"Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis Medicare patients"},{"title3":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy"},{"title3":"Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data"},{"title3":"Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis"},{"title3":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases"},{"title3":"Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study"},{"title3":"Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?"},{"title3":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994"},{"title3":"Healthcare resource utilization, demographics, and comorbidities in non-alcoholic fatty liver disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) and progressive stages in a large, integrated healthcare delivery system [Abstract]"},{"title3":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management"},{"title3":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes"},{"title3":"Prevalence of the metabolic syndrome in the United States, 2003-2012"},{"title3":"Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes"},{"title3":"Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large US claims database"},{"title3":"All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the united states: a managed care perspective"},{"title3":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis"},{"title3":"The co-existence of nash and chronic kidney disease boosts cardiovascular risk: are there any common therapeutic options?"},{"title3":"Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities"},{"title3":"NASH therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs"},{"title3":"Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease"},{"title3":"Estimating the real-world cost of diabetes mellitus in the united states during an 8-year period using 2 cost methodologies"},{"title3":"All-cause costs increase exponentially with increased chronic kidney disease stage"},{"title3":"Medical care costs among patients with established cardiovascular disease"},{"title3":"Vitamin D: a new player in non-alcoholic fatty liver disease?"},{"title3":"Effect of vitamin D on non-alcoholic fatty liver disease: a systematic review of randomized controlled clinical trials"},{"title3":"Vitamin D supplementation and non-alcoholic fatty liver disease: present and future"},{"title3":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis"},{"title3":"Truven health analytics marketscan databases for clinical research in colon and rectal surgery"}]},{"title2":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","References":[{"title3":"United Nations Sustainable Development Goals. UNDP"},{"title3":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016"},{"title3":"Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016"},{"title3":"Health effects of overweight and obesity in 195 countries over 25 years"},{"title3":"Maternal mortality: a cross-sectional study in global health"},{"title3":"Global causes of maternal death: a WHO systematic analysis"},{"title3":"A comparison of maternal mortality estimates from GBD 2013 and WHO"},{"title3":"Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013"},{"title3":"Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5"},{"title3":"The global burden of women's cancers: a grand challenge in global health"},{"title3":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis"},{"title3":"Breast cancer: a neglected disease for the majority of affected women worldwide"},{"title3":"Incidence and progression of cervical lesions in women with HIV: a systematic global review"},{"title3":"Estimating the prevalence of obstetric fistula: a systematic review and meta-analysis"},{"title3":"Vesico-vaginal fistula. The burden of maternal ill-health"},{"title3":"Burden of obstetric fistula: from measurement to action"},{"title3":"Obstetric fistula is a &quot;neglected tropical disease&quot;"},{"title3":"Surgically avertable burden of obstetric conditions in low- and middle-income regions: a modelled analysis"},{"title3":"Global, regional, and national age-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017"},{"title3":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement"},{"title3":"Department of Economic and Social Affairs. Population"},{"title3":"International Data Base (IDB)"},{"title3":"Disability weights for the Global Burden of Disease 2013 study"},{"title3":"Population and fertility by age and sex for 195 countries and territories 1950-2017: a systematic analysis for the Global Burden of Disease 2017"},{"title3":"Global, regional, and national age-specific and sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017"},{"title3":"The global HIV/AIDS epidemic:progress and challenges"},{"title3":"Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs"},{"title3":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States"},{"title3":"Hepatitis C can be cured globally, but at what cost?"},{"title3":"Hepatitis C drug affordability"},{"title3":"Associations between age, cohort, and urbanization with Sbp and Dbp in China: a population-based study across 18 years"},{"title3":"Height and prevalence of hypertension in a middle-aged and older Chinese population"},{"title3":"Factors associated with hypertension awareness, treatment, and control in a representative sample of the chinese population"},{"title3":"Explaining the decrease in US deaths from coronary disease, 1980-2000"},{"title3":"The global obesity pandemic: shaped by global drivers and local environments"},{"title3":"AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation"},{"title3":"2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines"},{"title3":"2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines"},{"title3":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)"},{"title3":"Out-of-hospital cardiac arrest survival improving over time: results from the Resuscitation Outcomes Consortium (ROC)"},{"title3":"Trends in survival after in-hospital cardiac arrest"},{"title3":"Survival from out-of-hospital cardiac arrest: are we beginning to see progress?"},{"title3":"Despite overall in-hospital cardiac arrest survival improvement, lower survival on nights, weekends persists"},{"title3":"Improving the UK's performance on survival after cardiac arrest"},{"title3":"Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-snalysis"},{"title3":"Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy clinical perspective: the treating to new targets (TNT) study"},{"title3":"Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review"},{"title3":"Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease"},{"title3":"Long-term oxygen therapy improves health-related quality of life"},{"title3":"Long-term home care programmes may reduce hospital admissions in COPD with chronic hypercapnia"},{"title3":"Influence of the oxygen delivery system on the quality of life of patients with chronic hypoxemia"},{"title3":"Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease?"},{"title3":"Evolution of physiological variables in patients with chronic obstructive pulmonary disease before and during long-term oxygen therapy"},{"title3":"Influenza vaccine for patients with chronic obstructive pulmonary disease"},{"title3":"Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study"},{"title3":"Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease"},{"title3":"Global and regional economic costs of dementia: a systematic review"},{"title3":"The economic burden of dementia in China, 1990-2030: implications for health policy"},{"title3":"World Alzheimer Report 2015 reveals global cost of dementia set to reach US $1 trillion by 2018"},{"title3":"Monetary costs of dementia in the United States"},{"title3":"Sex differences in autoimmune disease from a pathological perspective"},{"title3":"Sexual dimorphism in autoimmunity"},{"title3":"Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015"},{"title3":"Quality, equity, and dignity for women and babies"},{"title3":"Acute coronary syndromes in women: recent treatment trends and outcomes"},{"title3":"Cognition in males and females with autism: similarities and differences"},{"title3":"The autism spectrum screening questionnaire (ASSQ)-revised extended version (ASSQ-REV): an instrument for better capturing the autism phenotype in girls? A preliminary study involving 191 clinical cases and community controls"},{"title3":"A behavioral comparison of male and female adults with high functioning autism spectrum conditions"},{"title3":"Countries commit to strong action on human capital to drive economic growth"},{"title3":"Human capital: the greatest asset of economies on the rise"},{"title3":"Global cost of correcting vision impairment from uncorrected refractive error"},{"title3":"The global burden of potential productivity loss from uncorrected presbyopia"},{"title3":"Falls among persons aged &gt;=65 years with and without severe vision impairment:United States, 2014"},{"title3":"Visual risk factors for falls in older people"},{"title3":"The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, guxphysiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments"},{"title3":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study"},{"title3":"Platts-Mills J, Liu J, Rogawski E, et al. Aetiology, burden and clinical characteristics of diarrhoea in children in low-resource settings using quantitative molecular diagnostics: results from the MAL-ED cohort study. Lancet Glob Health (in press)."},{"title3":"Global burden of childhood pneumonia and diarrhoea"},{"title3":"Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries"},{"title3":"Updates to the Spectrum/Estimations and Projections Package model for estimating trends and current values for key HIV indicators"},{"title3":"Improving estimates of children living with HIV from the Spectrum AIDS Impact Model"},{"title3":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention"},{"title3":"Falls"},{"title3":"Road traffic injuries"},{"title3":"Burns"},{"title3":"Medical error:the third leading cause of death in the US"},{"title3":"Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015"},{"title3":"Medicare current beneficiary survey (MCBS)"}]},{"title2":"SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases","References":[{"title3":"Coronavirus as a possible cause of severe acute respiratory syndrome"},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"A cluster of cases of severe acute respiratory syndrome in Hong Kong"},{"title3":"Severe acute respiratory syndrome (SARS)"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study"},{"title3":"Hepatic regeneration in humans with various liver disease as assessed by Ki-67 staining of formalin-fixed paraffin-embedded liver tissue"},{"title3":"Enhanced detection of the coronavirus associated with severe acute respiratory syndrome (SARS)"},{"title3":"The genome seqence of the SARS-associated coronavirus"},{"title3":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"The nucleocapsid protein of murine hepatitis virus type 3 induces transcription of the novel fgl2 prothrombinase gene"},{"title3":"Comparison of mouse hepatitis virus strains for pathogenicity in weanling mice infected by various routes"},{"title3":"Mouse hepatitis virus type 4 (JHM strains) induced fatal central nervous system disease: genetic control and murine neuron as the susceptable site of disease"},{"title3":"Experimental demyelination produced by the A59 strain of mouse hepatitis virus"},{"title3":"Murine coronavirus spike glycoprotein: receptor binding and membrane fusion activities"},{"title3":"Coronavirus spike proteins in viral entry and pathogenesis"},{"title3":"Murine coronavirus spike protein determines the ability of the virus to replicate in the liver and cause hepatitis"},{"title3":"Quantitative analysis and prognostic implication of SARS-coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome"},{"title3":"Identification of severe acute respiratory syndrome in Canada"},{"title3":"Hepatocellular proliferation in patients with chronic hepatitis C and persistenly normal or abnormal aminotransferase level"},{"title3":"Liver regeneration is not altered in patients with nonalcoholic steatohepatitis (NASH) when compared to chronic hepatitis C infection with similar grade of inflammation"},{"title3":"Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division"},{"title3":"The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus"},{"title3":"Hepatic pathology resulting from mouse hepatitis virus S infection in severe combined immunodeficiency mice"},{"title3":"Induction of caspase-dependent apoptosis in cultured cells by the avian coronavirus infectious bronchitis virus"},{"title3":"The viral nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) is cleaved by caspase-6 and -7 during TGEV-induced apoptosis"},{"title3":"Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase"},{"title3":"Lung pathology of fatal severe acute respiratory syndrome"},{"title3":"Treatment-Kaletra"},{"title3":"Kaletra (lopinavir/ritonavir)"},{"title3":"Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection"},{"title3":"Mitochondrial toxic effects and ribavirin"},{"title3":"Liver disease in HIV: an update"},{"title3":"Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir"},{"title3":"Hepatotoxicity associated with ritonavir"},{"title3":"Budesonide-induced acute hepatitis in an HIV-positive patient with ritonavir as a co-medication"},{"title3":"Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir"},{"title3":"Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes"},{"title3":"Prolonged therapy of chronic hepatitis C with ribavirin"},{"title3":"Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study"},{"title3":"Incidence of and risk factors for severe hepatotoxicity associated with antiretorviral combination therapy"},{"title3":"Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine"},{"title3":"Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine cohort, France, 1996-1998"}]},{"title2":"Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection: clinicopathological and ultrastructural study","References":[{"title3":"Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV)"},{"title3":"Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection"},{"title3":"Renal complications and their prognosis in Korean patients with Middle East respiratory syndrome-coronavirus from the central MERS-CoV designated hospital"},{"title3":" In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) coronavirus infection"},{"title3":"Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014"},{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques"},{"title3":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC"},{"title3":"Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4"},{"title3":"Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission"},{"title3":"Middle East respiratory syndrome coronavirus (MERSCoV): perceptions, predictions, preventions and the pilgrimage"},{"title3":"MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2"},{"title3":"A case report of a Middle East respiratory syndrome survivor with kidney biopsy results"},{"title3":"Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series"},{"title3":"Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus"},{"title3":"Pathology and pathogenesis of severe acute respiratory syndrome"},{"title3":"SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases"}]},{"title2":"Liver injury in COVID-19: management and challenges","References":[{"title3":"The cytokine storm and COVID-19"},{"title3":"Kidney diseases and COVID-19 infection: causes and effect, supportive therapeutics and nutritional perspectives"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"COVID-19 and liver disease"},{"title3":"COVID-19 and the liver"},{"title3":"Liver Dysfunction Is Associated with Long-Term Mortality in Septic Shock"},{"title3":"Review article: COVID-19 and liver disease-what we know on 1st May 2020"},{"title3":"Gastrointestinal and liver manifestations in patients with COVID-19"},{"title3":"Liver diseases in COVID-19: Etiology, treatment and prognosis"},{"title3":"COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies"},{"title3":"Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis"},{"title3":"Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis"},{"title3":"A Case Series of Children With 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features"},{"title3":"Clinical characteristics of 82 cases of death from COVID-19"},{"title3":"Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort"},{"title3":"Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding"},{"title3":"SARS-CoV-2 Infection in Children"},{"title3":"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study"},{"title3":"Clinical Features of COVID-19-Related Liver Functional Abnormality"},{"title3":"Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China"},{"title3":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area"},{"title3":"Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series"},{"title3":"Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China"},{"title3":"Liver tests abnormalities in COVID-19: trick or treat?"},{"title3":"Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic"},{"title3":"Health Status of Patients Who Underwent Liver Transplantation During the Coronavirus Outbreak at a Large Center in Milan, Italy"},{"title3":"COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission"},{"title3":"COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract"},{"title3":"Liver injury in COVID-19: management and challenges"},{"title3":"Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease"},{"title3":"Coronavirus infections and immune responses"},{"title3":"Apoptosis: a mechanism of acute and chronic liver injury"},{"title3":"SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases"},{"title3":"Proteomics. Tissue-based map of the human proteome"},{"title3":"COVID-19 in a designated infectious diseases hospital outside Hubei Province, China"},{"title3":"Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)"},{"title3":"A literature review for the mechanisms of stress-induced liver injury"},{"title3":"Mechanisms and treatment of organ failure in sepsis"},{"title3":"Liver - guardian, modifier and target of sepsis"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"},{"title3":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase"},{"title3":"The emerging role of ACE2 in physiology and disease"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor"},{"title3":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein"},{"title3":"Human neutralizing antibodies elicited by SARS-CoV-2 infection"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes"},{"title3":"The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects"},{"title3":"A phase I trial of intravenous interleukin-6 in patients with advanced cancer"},{"title3":"Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells"},{"title3":"Systemic inflammation as fuel for acute liver injury in COVID-19"},{"title3":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality"},{"title3":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?"},{"title3":"Liver injury during highly pathogenic human coronavirus infections"},{"title3":"SARS-CoV-2: a storm is raging"},{"title3":"In the eye of the COVID-19 cytokine storm"},{"title3":"Viral and host factors related to the clinical outcome of COVID-19"},{"title3":"Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)"},{"title3":"Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China"},{"title3":"Use of lactate dehydrogenase to evaluate the anti-viral activity against influenza A virus"},{"title3":"Lactate dehydrogenase leakage as a marker for apoptotic cell degradation induced by influenza virus infection in human fetal membrane cells"},{"title3":"Adipokines: molecular links between obesity and atheroslcerosis"},{"title3":"A new perspective on C-reactive protein in H7N9 infections"},{"title3":"C-reactive protein as a biomarker of severe H1N1 influenza"},{"title3":"Cognitive decline in Parkinson disease"},{"title3":"Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Digestive Manifestations in Patients Hospitalized With Coronavirus Disease 2019"},{"title3":"Effect of Gastrointestinal Symptoms in Patients With COVID-19"},{"title3":"Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study"},{"title3":"AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19"},{"title3":"Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study"},{"title3":"Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19)"},{"title3":"COVID-19 and liver injury: where do we stand?"},{"title3":"Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection"},{"title3":"Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China"},{"title3":"Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement"},{"title3":"COVID-19: Abnormal liver function tests"},{"title3":"Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19"},{"title3":"Hepatic manifestations of COVID-19"},{"title3":"Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies"},{"title3":"Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis"},{"title3":"Acute Liver Failure in a COVID-19 Patient Without any Preexisting Liver Disease"},{"title3":"Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study"},{"title3":"Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19"},{"title3":"Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study"},{"title3":"Gastrointestinal and Hepatic Manifestations of COVID-19: Evolving Recognition and Need for Increased Understanding in Vulnerable Populations"},{"title3":"Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study"},{"title3":"COVID-19 in solid organ transplant recipients: A single-center case series from Spain"},{"title3":"COVID-19 in solid organ transplant recipients: Initial report from the US epicenter"},{"title3":"COVID-19 in solid organ transplantation patients: A systematic review"},{"title3":"Tocilizumab and liver injury in patients with COVID-19"},{"title3":"A Novel Coronavirus from Patients with Pneumonia in China, 2019"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor"},{"title3":"A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?"},{"title3":"Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19"},{"title3":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19"},{"title3":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir"},{"title3":"Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study"},{"title3":"Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives"},{"title3":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies"},{"title3":"The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design"},{"title3":"Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms"},{"title3":"Remdesivir for the Treatment of Covid-19 - Final Report"},{"title3":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19"},{"title3":"Liver injury in remdesivir-treated COVID-19 patients"},{"title3":"Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019"},{"title3":"Etiology and management of liver injury in patients with COVID-19"},{"title3":"Therapeutic Potential for Tetracyclines in the Treatment of COVID-19"},{"title3":"Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study"},{"title3":"Azithromycin augments rhinovirus-induced IFNbeta via cytosolic MDA5 in experimental models of asthma exacerbation"},{"title3":"Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 Levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis"},{"title3":"Azithromycin for COVID-19: More Than Just an Antimicrobial?"},{"title3":"Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective"},{"title3":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection"},{"title3":"First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19"},{"title3":"Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics"},{"title3":"Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine"},{"title3":"Liver Injury in COVID-19: Caution and Management"},{"title3":"Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient"},{"title3":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)"},{"title3":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review"},{"title3":"Tocilizumab and COVID-19"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report"},{"title3":"Polygalasaponin F treats mice with pneumonia induced by influenza virus"},{"title3":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study"},{"title3":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro"},{"title3":"The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells"},{"title3":"Ritonavir and Lopinavir Suppress RCE1 and CAAX Rab Proteins Sensitizing the Liver to Organelle Stress and Injury"},{"title3":"Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature"},{"title3":"Protective effect of bicyclol on lipopolysaccharide-induced acute lung injury in mice"},{"title3":"Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms"},{"title3":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study"},{"title3":"Current pharmacological treatments for COVID-19: What's next?"},{"title3":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity"},{"title3":"COVID-19: A review of the proposed pharmacological treatments"},{"title3":"Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis"},{"title3":"Chloroquine attenuates paraquat-induced lung injury in mice by altering inflammation, oxidative stress and fibrosis"},{"title3":"Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055"},{"title3":"The gut microbiota and host health: a new clinical frontier"},{"title3":"Contributions of the intestinal microbiome in lung immunity"},{"title3":"Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19"},{"title3":"Assessment of Renal and Hepatic Tissue-Protective Effects of N-Acetylcysteine via Ammonia Metabolism: A Prospective Randomized Study"},{"title3":"Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?"},{"title3":"Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke"},{"title3":"Could Vitamins Help in the Fight Against COVID-19?"},{"title3":"Role of vitamin E in nonalcoholic fatty liver disease"},{"title3":"Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths"},{"title3":"Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies"},{"title3":"Potential protection of vitamin C against liver-lesioned mice"},{"title3":"Zinc and COVID-19: Basis of Current Clinical Trials"},{"title3":"Zinc and liver disease"},{"title3":"Possibility of magnesium supplementation for supportive treatment in patients with COVID-19"},{"title3":"Magnesium and liver disease"},{"title3":"COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2"},{"title3":"Is copper beneficial for COVID-19 patients?"},{"title3":"Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats"},{"title3":"Corticosteroids in Acute Lung Injury: The Dilemma Continues"}]},{"title2":"Clinical features of COVID-19-related liver damage","References":[]},{"title2":"Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study","References":[]},{"title2":"High rates of 30-day mortality in patients with cirrhosis and COVID-19","References":[]},{"title2":"High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry","References":[{"title3":"Contemporary epidemiology of chronic liver disease and cirrhosis"},{"title3":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance"},{"title3":"Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper"},{"title3":"Cardiovascular disease, drug therapy, and mortality in Covid-19"},{"title3":"Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010"},{"title3":"Influenza virus infection as precipitating event of acute-on-chronic liver failure"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"}]},{"title2":"Guidance for certifying deaths due to coronavirus disease 2019 (COVID-19). National Center for Health Statistics","References":[]},{"title2":"Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease","References":[]},{"title2":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","References":[{"title3":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China"},{"title3":"Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak"},{"title3":"Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City"},{"title3":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients"},{"title3":"COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020"},{"title3":"Crowdsourcing a crisis response for COVID-19 in oncology"},{"title3":"Research electronic data capture (REDCap):a metadata-driven methodology and workflow process for providing translational research informatics support"},{"title3":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach"},{"title3":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors"},{"title3":"RegularIZation and variable selection via the elastic net"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Case fatality rate of cancer patients with COVID-19 in a New York hospital system"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area"},{"title3":"Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2"},{"title3":"Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2"},{"title3":"Facing Covid-19 in Italy - ethics, logistics, and therapeutics on the epidemic's front line"},{"title3":"Ethics and resource scarcity: ASCO recommendations for the oncology community during the COVID-19 pandemic"},{"title3":"Inflammatory diseases of the lung induced by conventional cigarette smoke: a review"},{"title3":"Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review"},{"title3":"Sex difference and smoking predisposition in patients with COVID-19"},{"title3":"COVID-19 and smoking: a systematic review of the evidence"},{"title3":"Cigarette smoke triggers the expansion of a subpopulation of respiratory epithelial cells that express the SARS-CoV-2 receptor ACE2"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19"},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2"},{"title3":"Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia"},{"title3":"TMPRSS2 and COVID-19: serendipity or opportunity for intervention?"},{"title3":"COVID-19 Response Team. Characteristics of health care personnel with COVID-19 - United States, February 12-April 9, 2020"},{"title3":"Effects of delayed surgical resection on short-term and long-term outcomes in clinical stage I non-small cell lung cancer"},{"title3":"Time to surgery and breast cancer survival in the United States"},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"},{"title3":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19"}]},{"title2":"Coronavirus disease 2019: people with certain medical conditions. CDC","References":[]},{"title2":"Hepatic decompensation in patients with cirrhosis during infection with influenza A","References":[]},{"title2":"Influenza virus infection as precipitating event of acute-on-chronic liver failure","References":[]},{"title2":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","References":[]},{"title2":"Infection and alcoholic liver disease","References":[]},{"title2":"Recent advances of sterile inflammation and inter-organ cross-talk in alcoholic liver disease","References":[{"title3":"Alcohol, liver disease and the gut microbiota"},{"title3":"Hepatic non-parenchymal cells: master regulators of alcoholic liver disease?"},{"title3":"Hepatic stellate cells and innate immunity in alcoholic liver disease"},{"title3":"Gut-liver axis in alcoholic liver disease"},{"title3":"Inflammatory pathways in alcoholic steatohepatitis"},{"title3":"Carcinogenic etheno DNA adducts in alcoholic liver disease: correlation with cytochrome P-4502E1 and fibrosis"},{"title3":"CYP2E1 and oxidative liver injury by alcohol"},{"title3":"High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD)"},{"title3":"Mitochondrial DNA-enriched microparticles promote acute-on-chronic alcoholic neutrophilia and hepatotoxicity"},{"title3":"Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice"},{"title3":"The inflammasomes"},{"title3":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice"},{"title3":"Extracellular vesicles in liver pathobiology: small particles with big impact"},{"title3":"Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood"},{"title3":"MicroRNA cargo of extracellular vesicles from alcohol-exposed monocytes signals naive monocytes to differentiate into M2 macrophages"},{"title3":"Mitochondrial double-stranded RNA triggers antiviral signalling in humans"},{"title3":"Lee, J. H. et al. Mitochondrial double-stranded RNA in exosome promotes interleukin-17 production through toll-like receptor 3 in alcoholic liver injury. Hepatology (2019) [Ahead of print]."},{"title3":"Exosome-mediated activation of toll-like receptor 3 in stellate cells stimulates interleukin-17 production by gammadelta T cells in liver fibrosis"},{"title3":"Activation of toll-like receptor 3 attenuates alcoholic liver injury by stimulating Kupffer cells and stellate cells to produce interleukin-10 in mice"},{"title3":"Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9"},{"title3":"ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles"},{"title3":"Extracellular vesicles from mice with alcoholic liver disease carry a distinct protein cargo and induce macrophage activation through heat shock protein 90"},{"title3":"Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles"},{"title3":"Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver"},{"title3":"Glutamate signaling in hepatic stellate cells drives alcoholic steatosis"},{"title3":"Current concepts in the pathogenesis of alcoholic liver injury"},{"title3":"Retinoic acids and hepatic stellate cells in liver disease"},{"title3":"Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice"},{"title3":"STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity"},{"title3":"Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis"},{"title3":"Suppression of innate immunity (natural killer cell/interferon-gamma) in the advanced stages of liver fibrosis in mice"},{"title3":"Blockade of retinol metabolism protects T cell-induced hepatitis by increasing migration of regulatory T cells"},{"title3":"Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals"},{"title3":"Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis"},{"title3":"Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver"},{"title3":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae"},{"title3":"Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations"},{"title3":"Targeting adipose tissue in the treatment of obesity-associated diabetes"},{"title3":"Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria"},{"title3":"Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis"},{"title3":"Binge drinking induces whole-body insulin resistance by impairing hypothalamic insulin action"},{"title3":"Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes"},{"title3":"Chronic ethanol consumption increases plasma leptin levels and alters leptin receptors in the hypothalamus and the perigonadal fat of C57BL/6 mice"},{"title3":"Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis"},{"title3":"Alcohol withdrawal alleviates adipose tissue inflammation in patients with alcoholic liver disease"},{"title3":"Identification of a cytochrome P4502E1/Bid/C1q-dependent axis mediating inflammation in adipose tissue after chronic ethanol feeding to mice"},{"title3":"Obesity is associated with macrophage accumulation in adipose tissue"},{"title3":"Adipose inflammation and macrophage infiltration after binge ethanol and burn injury"},{"title3":"Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease"},{"title3":"Properties and functions of adipose tissue macrophages in obesity"},{"title3":"Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway"},{"title3":"Anti-inflammatory pathways and alcoholic liver disease: role of an adiponectin/interleukin-10/heme oxygenase-1 pathway"},{"title3":"Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals"},{"title3":"Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells"},{"title3":"The role of innate immunity in alcoholic liver disease"},{"title3":"Anaphylatoxin receptors C3aR and C5aR1 are important factors that influence the impact of ethanol on the adipose secretome"},{"title3":"Regional specialization within the intestinal immune system"},{"title3":"Leukocyte trafficking to the small intestine and colon"},{"title3":"Maintenance of gut homeostasis by the mucosal immune system"},{"title3":"Introduction to the human gut microbiota"},{"title3":"Colonic microbiome is altered in alcoholism"},{"title3":"Use of measurements of ethanol absorption from stomach and intestine to assess human ethanol metabolism"},{"title3":"Ethanol metabolism and its effects on the intestinal epithelial barrier"},{"title3":"Intestinal CYP2E1: a mediator of alcohol-induced gut leakiness"},{"title3":"Cho, Y. E. et al. Fructose promotes leaky gut, endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P450-2E1-mediated oxidative and nitrative stress. Hepatology (2019) [Ahead of print]."},{"title3":"Role for intestinal CYP2E1 in alcohol-induced circadian gene-mediated intestinal hyperpermeability"},{"title3":"The gut-liver axis and the intersection with the microbiome"},{"title3":"Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease"},{"title3":"Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia"},{"title3":"Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14"},{"title3":"Enteric dysbiosis associated with a mouse model of alcoholic liver disease"},{"title3":"Characterization of fecal microbial communities in patients with liver cirrhosis"},{"title3":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease"},{"title3":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae"},{"title3":"Intestinal fungi contribute to development of alcoholic liver disease"},{"title3":"Role of inflammatory pathways, blood mononuclear cells, and gut-derived bacterial products in alcohol dependence"},{"title3":"Pro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol"},{"title3":"Impaired intestinal immunity and barrier function: a cause for enhanced bacterial translocation in alcohol intoxication and burn injury"},{"title3":"Neutrophil chemokines and their role in IL-18-mediated increase in neutrophil O2- production and intestinal edema following alcohol intoxication and burn injury"},{"title3":"Ethanol-induced depletion of lymphocytes from the mesenteric lymph nodes of C57B1/6 mice is associated with RNA but not DNA degradation"},{"title3":"Gut-associated lymphoid T cell suppression enhances bacterial translocation in alcohol and burn injury"},{"title3":"ERK and not p38 pathway is required for IL-12 restoration of T cell IL-2 and IFN-gamma in a rodent model of alcohol intoxication and burn injury"},{"title3":"Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease"},{"title3":"Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis"},{"title3":"TLR4 enhances TGF-beta signaling and hepatic fibrosis"},{"title3":"Bone marrow and the control of immunity"},{"title3":"Monocyte recruitment during infection and inflammation"},{"title3":"Neutrophils as protagonists and targets in chronic inflammation"},{"title3":"Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy"},{"title3":"CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice"},{"title3":"Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial"},{"title3":"Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial"},{"title3":"Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial"},{"title3":"Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study"},{"title3":"G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs"},{"title3":"CX3CR1 differentiates F4/80(low) monocytes into pro-inflammatory F4/80(high) macrophages in the liver"},{"title3":"Stellate cells, hepatocytes, and endothelial cells imprint the kupffer cell identity on monocytes colonizing the liver macrophage niche"},{"title3":"Liver-derived signals sequentially reprogram myeloid enhancers to initiate and maintain kupffer cell identity"}]},{"title2":"Gut-liver axis in alcoholic liver disease","References":[]},{"title2":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","References":[{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice"},{"title3":"Targeting the 'cytokine storm' for therapeutic benefit"},{"title3":"Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome"},{"title3":"Proteinase-activated receptors in fibroproliferative lung disease"},{"title3":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia"},{"title3":"Findings of acute pulmonary embolism in COVID-19 patients"},{"title3":"Vorapaxar in the secondary prevention of atherothrombotic events"},{"title3":"Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia"},{"title3":"Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection"},{"title3":"PAR-1 contributes to the innate immune response during viral infection"},{"title3":"PAR1 contributes to influenza A virus pathogenicity in mice"}]},{"title2":"COVID-19 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease","References":[]},{"title2":"Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis?","References":[{"title3":"Stress, dysregulation of drug reward pathways, and the transition to drug dependence"},{"title3":"Effect of social isolation on stress-related behavioural and neuroendocrine state in the rat"},{"title3":"The role of stress-reactivity, stress-recovery and risky decision-making in psychosocial stress-induced alcohol consumption in social drinkers"},{"title3":"Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction"}]},{"title2":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","References":[{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"A novel coronavirus outbreak of global health concern"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Nosocomial infections in patients with cancer"},{"title3":"Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer"},{"title3":"Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways"},{"title3":"Myeloid suppressor cells in cancer and autoimmunity"},{"title3":"Report of cancer epidemiology in China, 2015"}]},{"title2":"Characteristics of adult outpatients and inpatients with COVID-19: 11 academic medical centers, United States, March-May 2020","References":[{"title3":"COVID-19 among workers in meat and poultry processing facilities:19 states, April 2020."},{"title3":"Epidemiology of Covid-19 in a long-term care facility in King County, Washington."},{"title3":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application."},{"title3":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019:COVID-NET, 14 states, March 1-30, 2020."},{"title3":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy"},{"title3":"Influenza vaccine effectiveness in inpatient and outpatient settings in the United States, 2015-2018."},{"title3":"Illness severity and work productivity loss among working adults with medically attended acute respiratory illnesses: US Influenza Vaccine Effectiveness Network 2012-2013"}]},{"title2":"Atlanta, GA: US Department of Health and Human Services, CDC","References":[]}]}]}